From Wikipedia, the free encyclopedia
- For other depressive disorders, see Types of psychological depression.
Major depressive disorder (also known as clinical depression, major depression, unipolar depression, or unipolar disorder) is a mental disorder characterized by an all-encompassing low mood accompanied by low self-esteem, and loss of interest or pleasure in normally enjoyable activities. The term "major depressive disorder" was selected by the American Psychiatric Association to designate this symptom cluster as a mood disorder in the 1980 version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) classification, and has become widely used since. The general term depression is often used to denote the disorder, but as it can also be used in reference to other types of psychological depression, more precise terminology is preferred for the disorder in clinical and research use. Major depression is a disabling condition which adversely affects a person's family, work or school life, sleeping and eating habits, and general health. In the United States, approximately 3.4% of people with major depression commit suicide, and up to 60% of people who commit suicide have depression or another mood disorder.
The diagnosis of major depressive disorder is based on the patient's self-reported experiences, behavior reported by relatives or friends, and a mental status exam. There is no laboratory test for major depression, although physicians generally request tests for physical conditions that may cause similar symptoms. The most common time of onset is between the ages of 20 and 30 years, with a later peak between 30 and 40 years. Major depression is reported about twice as frequently in women as in men, and women attempt suicide more often, although men are at higher risk for completing suicide.
Most patients are treated in the community with antidepressant medication and some with psychotherapy or counselling. Hospitalization may be necessary in cases with associated self-neglect or a significant risk of harm to self or others. A minority are treated with electroconvulsive therapy (ECT), under a short-acting general anaesthetic. The course of the disorder varies widely, from one episode lasting months to a lifelong disorder with recurrent major depressive episodes. Depressed individuals have shorter life expectancies than those without depression, in part because of greater susceptibility to medical illnesses and suicide. Current and former patients may be stigmatized.
The understanding of the nature and causes of depression has evolved over the centuries, though this understanding is incomplete and many aspects of depression are still the subject of discussion and research. Proposed causes include psychological, psycho-social, hereditary, evolutionary and biological factors. Psychological treatments are based on theories of personality, interpersonal communication, and learning. Most biological theories focus on the monoamine chemicals serotonin, norepinephrine and dopamine, which are naturally present in the brain and assist communication between nerve cells. Monoamines have been implicated in depression, and most antidepressants work to increase the active levels of at least one.
Symptoms and signs
Major depression is a serious illness that affects a person's family and personal relationships, work or school life, sleeping and eating habits, and general health. Its impact on functioning and well-being has been equated to that of chronic medical conditions such as diabetes.
A person suffering a major depressive episode usually exhibits a very low mood, which pervades all aspects of life, and an inability to experience pleasure in activities that formerly were enjoyed. Depressed people may be preoccupied with, or ruminate over, thoughts and feelings of worthlessness, inappropriate guilt or regret, helplessness, hopelessness, and self-hatred. In severe cases, depressed people may have symptoms of psychosis. These symptoms include delusions or, less commonly, hallucinations, usually of an unpleasant nature. Other symptoms of depression include poor concentration and memory (especially in those with melancholic or psychotic features), withdrawal from social situations and activities, reduced sex drive, and thoughts of death or suicide.
Insomnia is common among the depressed. In the typical pattern, a person wakes very early and is unable to get back to sleep. Hypersomnia, or oversleeping, is less common. Appetite often decreases, with resulting weight loss, although increased appetite and weight gain occasionally occur. The person may report multiple physical symptoms such as fatigue, headaches, or digestive problems; physical complaints are the most common presenting problem in developing countries, according to the World Health Organization's criteria for depression. Family and friends may notice that the person's behavior is either agitated or lethargic.
Depressed children often display an irritable rather than a depressed mood, and show varying symptoms depending on age and situation. Most exhibit a loss of interest in school and a decline in academic performance. They may be described as clingy, demanding, dependent, or insecure. Diagnosis may be delayed or missed when symptoms are interpreted as normal moodiness. Depression may also coincide with attention-deficit hyperactivity disorder (ADHD), complicating the diagnosis and treatment of both.
Older depressed persons may have cognitive symptoms of recent onset, such as forgetfulness, and a more noticeable slowing of movements. Depression often coexists with physical disorders common among the elderly, such as stroke, other cardiovascular diseases, Parkinson's disease, and chronic obstructive pulmonary disease.
The biopsychosocial model proposes that biological, psychological, and social factors all play a role to varying degrees in causing depression. The diathesis–stress model posits that depression results when a preexisting vulnerability, or diathesis, is activated by stressful life events. The preexisting vulnerability can be either genetic, implying an interaction between nature and nurture, or schematic, resulting from views of the world learned in childhood. These interactive models have gained empirical support. For example, researchers in New Zealand took a prospective approach to studying depression, by documenting over time how depression emerged among an initially normal cohort of people. The researchers concluded that variation among the serotonin transporter (5-HTT) gene affects the chances that people who have dealt with very stressful life events will go on to experience depression. Specifically, depression may follow such events, but seems more likely to appear in people with one or two short alleles of the 5-HTT gene.
A Swedish study estimated the heritability of depression—the degree to which individual differences in occurrence are associated with genetic differences—to be approximately 40% for women and 30% for men, and evolutionary psychologists have proposed that the genetic basis for depression lies deep in the history of naturally selected adaptations. A substance-induced mood disorder resembling major depression has been causally linked to long-term drug use or abuse, or to withdrawal from certain sedative and hypnotic drugs.
Most antidepressant medications increase the levels of one or more of the monoamines—the neurotransmitters serotonin, norepinephrine and dopamine—in the synaptic cleft between neurons in the brain. Some medications affect the monoamine receptors directly.
Serotonin is hypothesized to help regulate other neurotransmitter systems; decreased serotonin activity may allow these systems to act in unusual and erratic ways. According to this "permissive hypothesis", depression arises when low serotonin levels promote low levels of norepinephrine, another monoamine neurotransmitter. Some antidepressants enhance the levels of norepinephrine directly, whereas others raise the levels of dopamine, a third monoamine neurotransmitter. These observations gave rise to the monoamine hypothesis of depression. In its contemporary formulation, the monoamine hypothesis postulates that a deficiency of certain neurotransmitters is responsible for the corresponding features of depression: "Norepinephrine may be related to alertness and energy as well as anxiety, attention, and interest in life; [lack of] serotonin to anxiety, obsessions, and compulsions; and dopamine to attention, motivation, pleasure, and reward, as well as interest in life." The proponents of this theory recommend the choice of an antidepressant with mechanism of action that impacts the most prominent symptoms. Anxious and irritable patients should be treated with SSRIs or norepinephrine reuptake inhibitors, and those experiencing a loss of energy and enjoyment of life with norepinephrine- and dopamine-enhancing drugs.
Schematic of a synapse
between an axon of one neuron
and a dendrite
of another. Synapses are specialized gaps between neurons. Electrical impulses
arriving at the axon terminal trigger release of packets of chemical messengers (neurotransmitters
), which diffuse across the synaptic cleft to receptors
on the adjacent dendrite temporarily affecting the likelihood that an electrical impulse
will be triggered in the latter neuron. Once released the neurotransmitter is rapidly metabolized or pumped back into a neuron. Antidepressants influence the overall balance of these processes.
In the past two decades, research has revealed multiple limitations of the monoamine hypothesis, and its explanatory inadequacy has been criticized within the psychiatric community. Intensive investigation has failed to find convincing evidence of a primary dysfunction of a specific monoamine system in patients with major depressive disorders. The medications tianeptine and opipramol have long been known to have antidepressant properties despite the fact that the former is a serotonin reuptake enhancer and the latter has no effect on the monoamine system. Experiments with pharmacological agents that cause depletion of monoamines have shown that this depletion does not cause depression in healthy people nor does it worsen symptoms in depressed patients—although an intact monoamine system is necessary for antidepressants to achieve therapeutic effectiveness. According to an essay published by the Public Library of Science (PLoS), the monoamine hypothesis, already limited, has been further oversimplified when presented to the general public as a mass marketing tool.
MRI scans of patients with depression have reported a number of differences in brain structure compared to those without the illness. Although there is some inconsistency in the results, meta-analyses have shown there is evidence for smaller hippocampal volumes and increased numbers of hyperintensive lesions. Hyperintensities have been associated with patients with a late age of onset, and have led to the development of the theory of vascular depression.
There may be a link between depression and neurogenesis of the hippocampus, a center for both mood and memory. Loss of hippocampal neurons is found in some depressed individuals and correlates with impaired memory and dysthymic mood. Drugs may increase serotonin levels in the brain, stimulating neurogenesis and thus increasing the total mass of the hippocampus. This increase may help to restore mood and memory. Similar relationships have been observed between depression and an area of the anterior cingulate cortex implicated in the modulation of emotional behavior. One of the neurotrophins responsible for neurogenesis is the brain-derived neurotrophic factor (BDNF). The level of BDNF in the blood plasma of depressed subjects is drastically reduced (more than threefold) as compared to the norm. Antidepressant treatment increases the blood level of BDNF. Although decreased plasma BDNF levels have been found in many other disorders, there is some evidence that BDNF is involved in the cause of depression and the mechanism of action of antidepressants.
There is evidence that Major depression may be caused in part by an overactive hypothalamic-pituitary-adrenal axis (HPA axis) that results in an effect similar to the neuro-endocrine response to stress. Investigations reveal increased levels of the hormone cortisol and enlarged pituitary and adrenal glands, suggesting disturbances of the endocrine system may play a role in some psychiatric disorders, including major depression. Oversecretion of corticotropin-releasing hormone from the hypothalamus is thought to drive this, and is implicated in the cognitive and arousal symptoms.
Depression may be related to the same brain mechanisms that control the cycles of sleep and wakefulness.
Depression may be related to abnormalities in the circadian rhythm, or biological clock. For example, the REM stage of sleep, the one in which dreaming occurs, may be quick to arrive and intense in depressed people. REM sleep depends on decreased serotonin levels in the brain stem, and is impaired by compounds, such as antidepressants, that increase serotonergic tone in brain stem structures. Overall, the serotonergic system is least active during sleep and most active during wakefulness. Prolonged wakefulness due to sleep deprivation activates serotonergic neurons, leading to processes similar to the therapeutic effect of antidepressants, such as the selective serotonin reuptake inhibitors (SSRIs). Depressed individuals can exhibit a significant lift in mood after a night of sleep deprivation. SSRIs may directly depend on the increase of central serotonergic neurotransmission for their therapeutic effect, the same system that impacts cycles of sleep and wakefulness.
Research on the effects of light therapy on treating seasonal affective disorder suggests that light deprivation is related to decreased activity in the serotonergic system and to abnormalities in the sleep cycle, particularly insomnia. Exposure to light also targets the serotonergic system, providing more support for the important role this system may play in depression. Sleep deprivation and light therapy both target the same brain neurotransmitter system and brain areas as antidepressant drugs, and are now used clinically to treat depression. Light therapy, sleep deprivation and sleep time displacement (sleep phase advance therapy) are being used in combination quickly to interrupt a deep depression in hospitalized patients.
The hormone estrogen has been implicated in depressive disorders due to the increase in risk of depressive episodes after puberty, the antenatal period, and reduced rates after menopause. Conversely, the premenstrual and postpartum periods of low estrogen levels are also associated with increased risk. Sudden withdrawal of, fluctuations in or periods of sustained low levels of estrogen have been linked to significant mood lowering. Clinical recovery from depression postpartum, perimenopause, and postmenopause was shown to be effective after levels of estrogen were stabilized or restored. Other research has explored potential roles of molecules necessary for overall cellular functioning: cytokines. The symptoms of major depressive disorder are nearly identical to those of sickness behavior, the response of the body when the immune system is fighting an infection. This raises the possibility that depression can result from a maladaptive manifestation of sickness behavior as a result of abnormalities in circulating cytokines.
Various aspects of personality and its development appear to be integral to the occurrence and persistence of depression, with negative emotionality as a common precursor. Although depressive episodes are strongly correlated with adverse events, a person's characteristic style of coping may be correlated with their resilience. Additionally, low self-esteem and self-defeating or distorted thinking are related to depression. Depression is less likely to occur, as well as quicker to remit, among those who are religious. It is not always clear which factors are causes or which are effects of depression; however, depressed persons who are able to make corrections in their thinking patterns often show improved mood and self-esteem.
American psychiatrist Aaron T. Beck developed what is now known as a cognitive model of depression in the early 1960s. He proposed that three concepts underlie depression: a triad of negative thoughts composed of cognitive errors about oneself, one's world, and one's future; recurrent patterns of depressive thinking, or schemas; and distorted information processing. From these principles, he developed the structured technique of cognitive behavioral therapy (CBT). According to American psychologist Martin Seligman, depression in humans is similar to learned helplessness in laboratory animals, who remain in unpleasant situations when they are able to escape, but do not because they initially learned they had no control.
Depressed individuals often blame themselves for negative events, and a 1993 study of hospitalized adolescents with self-reported depression shows that those who do this may not take credit for positive outcomes. This tendency is characteristic of a depressive attributional, or pessimistic explanatory style. According to Albert Bandura, a Canadian social psychologist associated with social cognitive theory, depressed individuals have negative beliefs about themselves, based on experiences of failure, observing the failure of social models, a lack of social persuasion that they can succeed, and their own somatic and emotional states including tension and stress. These influences may result in a negative self-concept and a perceived lack of self-efficacy; that is, they do not believe they can influence events or achieve personal goals.
An examination of depression in women indicates that vulnerability factors—such as early maternal loss, lack of a confiding relationship, responsibility for the care of several young children at home, and unemployment—can interact with life stressors to increase the risk of depression. For older adults, the factors are often health problems, changes in relationships with a spouse or adult children due to the transition to a care-giving or care-needing role, the death of a significant other, or a change in the availability or quality of social relationships with older friends because of their own health-related life changes.
The understanding of depression has also received contributions from the psychoanalytic and humanistic branches of psychology. From the classical psychoanalytic perspective of Austrian psychiatrist Sigmund Freud, depression, or melancholia, may be related to interpersonal loss and early life experiences. Existential therapists have connected depression to the lack of both meaning in the present and a vision of the future. The founder of humanistic psychology, American psychologist Abraham Maslow, suggested that depression could arise when people are unable to attain their needs or to self-actualize, to realize their full potential.
Poverty and social isolation are associated with increased risk of psychiatric problems in general. Child abuse (physical, emotional, sexual, or neglect) is also associated with increased risk of developing depressive disorders later in life. Disturbances in family functioning, such as parental (particularly maternal) depression, severe marital conflict or divorce, death of a parent, or other disturbances in parenting are additional risk factors. In adulthood, stressful life events are strongly associated with the onset of major depressive episodes. In this context, life events connected to social rejection appear to be particularly related to depression. Consistent with the hypothesis that people may become increasingly sensitized to life stress over successive recurrences of depression is evidence that a first episode is more likely to be immediately preceded by stressful life events than are recurrent ones.
The relationship between stressful life events and social support has been a matter of some debate; the lack of social support may increase the likelihood that life stress will lead to depression, or the absence of social support may constitute a form of strain that leads to depression directly. There is evidence that neighborhood social disorder, for example, due to crime or illicit drugs, is a risk factor, and that a high neighborhood socioeconomic status, with better amenities, is a protective factor. Adverse conditions at work, particularly demanding jobs with little scope for decision-making, are associated with depression, although diversity and confounding factors make it difficult to confirm that the relationship is causal.
From the standpoint of evolutionary theory, major depression is hypothesized, in some instances, to increase an individual's ability to reproduce. Evolutionary approaches to depression and evolutionary psychology posit specific mechanisms by which depression may have been genetically incorporated into the human gene pool, accounting for the high heritability and prevalence of depression by proposing that certain components of depression are adaptations, such as the behaviors relating to attachment and social rank. Current behaviors can be explained as adaptations to regulate relationships or resources, although the result may be maladaptive in modern environments.
From another viewpoint, a counseling therapist may see depression, not as a biochemical illness or disorder, but as "a species-wide evolved suite of emotional programmes that are mostly activated by a perception, almost always over-negative, of a major decline in personal usefulness, that can sometimes be linked to guilt, shame or perceived rejection". This suite may have manifested in aging hunters in humans' foraging past, who were marginalized by their declining skills, and may continue to appear in alienated members of today's society. The feelings of uselessness generated by such marginalization could hypothetically prompt support from friends and kin. Additionally, in a manner analogous to that in which physical pain has evolved to hinder actions that may cause further injury, "psychic misery" may have evolved to prevent hasty and maladaptive reactions to distressing situations.
Drug and alcohol use
The DSM precludes a diagnosis of major depressive disorder for those presenting with "the direct physiological effects of a substance" because sedative hypnotic drugs such as alcohol and benzodiazepines increase the risk of a syndrome that is similar to major depression. This increased risk may be due in part to the effects of drugs on neurochemistry, such as decreased levels of serotonin and norepinephrine. Alcoholism or excessive alcohol consumption significantly increases the risk of developing this syndrome. Chronic use of benzodiazepines, a class of medication that is commonly used to treat insomnia, anxiety and muscular spasms, also increases the risk. Chronic, severe depression can develop as a result of chronic use of benzodiazepines or as part of a protracted withdrawal syndrome.
A diagnostic assessment may be conducted by a general practitioner, or by a psychiatrist or psychologist, who records the person's current circumstances, biographical history and current symptoms, and a family medical history to see if other family members have suffered from a mood disorder, and discusses the person's alcohol and drug use. The assessment also includes a mental state examination, which is an assessment of the person's current mood and thought content, in particular the presence of themes of hopelessness or pessimism, self-harm or suicide, and an absence of positive thoughts or plans. Specialist mental health services are rare in rural areas, and thus diagnosis and management is largely left to primary care clinicians. This issue is even more marked in developing countries. The score on a rating scale alone is not sufficient to diagnose depression, but it provides an indication of the severity of symptoms for a time period, so a person who scores above a given cut-off point can be more thoroughly evaluated for a depressive disorder diagnosis. Several rating scales are used for this purpose. Screening programs have been advocated to improve detection of depression, but there is evidence that they do not improve detection rates, treatment, or outcome.
Primary care physicians and other non-psychiatrist physicians have difficulty diagnosing depression. Non-psychiatrists miss two-thirds of cases and unnecessarily treat other patients.
Before diagnosing a major depressive disorder, a doctor generally performs a medical examination and selected investigations to rule out other causes of symptoms. These include blood tests measuring TSH and thyroxine to exclude hypothyroidism; basic electrolytes and serum calcium to rule out a metabolic disturbance; and a full blood count including ESR to rule out a systemic infection or chronic disease. Adverse affective reactions to medications or alcohol misuse are often ruled out, as well. Testosterone levels may be evaluated to diagnose hypogonadism, a cause of depression in men.
Subjective cognitive complaints appear in older depressed people, but they can also be indicative of the onset of a dementing disorder, such as Alzheimer's disease. Cognitive testing and brain imaging can help distinguish depression from dementia. A CT scan can exclude brain pathology in those with psychotic, rapid-onset or otherwise unusual symptoms. No biological tests confirm major depression. Investigations are not generally repeated for a subsequent episode unless there is a medical indication.
DSM-IV-TR and ICD-10 criteria
The most widely used criteria for diagnosing depressive conditions are found in the American Psychiatric Association's revised fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), and the World Health Organization's International Statistical Classification of Diseases and Related Health Problems (ICD-10) which uses the name recurrent depressive disorder. The latter system is typically used in European countries, while the former is used in the US and many other non-European nations, and the authors of both have worked towards conforming one with the other.
Major depressive disorder is classified as a mood disorder in DSM-IV-TR. The diagnosis hinges on the presence of single or recurrent major depressive episodes. Further qualifiers are used to classify both the episode itself and the course of the disorder. The category Depressive disorder not otherwise specified is diagnosed if the depressive episode's manifestation does not meet the criteria for a major depressive episode. The ICD-10 system does not use the term Major depressive disorder, but lists very similar criteria for the diagnosis of a depressive episode (mild, moderate or severe); the term recurrent may be added if there have been multiple episodes without mania.
Major depressive episode
A major depressive episode is characterized by the presence of a severely depressed mood that persists for at least two weeks. Episodes may be isolated or recurrent and are categorized as mild (few symptoms in excess of minimum criteria), moderate, or severe (marked impact on social or occupational functioning). An episode with psychotic features—commonly referred to as psychotic depression—is automatically rated as severe. If the patient has had an episode of mania or markedly elevated mood, a diagnosis of bipolar disorder is made instead. Depression without mania is sometimes referred to as unipolar because the mood remains at one emotional state or "pole".
DSM-IV-TR excludes cases where the symptoms are a result of bereavement, although it is possible for normal bereavement to evolve into a depressive episode if the mood persists and the characteristic features of a major depressive episode develop. The criteria have been criticized because they do not take into account any other aspects of the personal and social context in which depression can occur. In addition, some studies have found little empirical support for the DSM-IV cut-off criteria, indicating they are a diagnostic convention imposed on a continuum of depressive symptoms of varying severity and duration: excluded are a range of related diagnoses, including dysthymia which involves a chronic but milder mood disturbance, Recurrent brief depression which involves briefer depressive episodes, minor depressive disorder which involves only some of the symptoms of major depression, and adjustment disorder with depressed mood which involves low mood resulting from a psychological response to an identifiable event or stressor.
The DSM-IV-TR recognizes five further subtypes of MDD, called specifiers, in addition to noting the length, severity and presence of psychotic features:
- Melancholic depression is characterized by a loss of pleasure in most or all activities, a failure of reactivity to pleasurable stimuli, a quality of depressed mood more pronounced than that of grief or loss, a worsening of symptoms in the morning hours, early morning waking, psychomotor retardation, excessive weight loss (not to be confused with anorexia nervosa), or excessive guilt.
- Atypical depression is characterized by mood reactivity (paradoxical anhedonia) and positivity, significant weight gain or increased appetite (comfort eating), excessive sleep or sleepiness (hypersomnia), a sensation of heaviness in limbs known as leaden paralysis, and significant social impairment as a consequence of hypersensitivity to perceived interpersonal rejection.
- Catatonic depression is a rare and severe form of major depression involving disturbances of motor behavior and other symptoms. Here the person is mute and almost stuporose, and either remains immobile or exhibits purposeless or even bizarre movements. Catatonic symptoms also occur in schizophrenia or in manic episodes, or may be caused by neuroleptic malignant syndrome.
- Postpartum depression (Mild mental and behavioral disorders associated with the puerperium, not elsewhere classified in ICD-10) refers to the intense, sustained and sometimes disabling depression experienced by women after giving birth. Postpartum depression, which has incidence rate of 10–15% among new mothers, typically sets in within three months of labor, and lasts as long as three months.
- Seasonal affective disorder (SAD) is a form of depression in which depressive episodes come on in the autumn or winter, and resolve in spring. The diagnosis is made if at least two episodes have occurred in colder months with none at other times, over a two-year period or longer.
To confer major depressive disorder as the most likely diagnosis, other potential diagnoses must be considered, including dysthymia, adjustment disorder with depressed mood or bipolar disorder. Dysthymia is a chronic, milder mood disturbance in which a person reports a low mood almost daily over a span of at least two years. The symptoms are not as severe as those for major depression, although people with dysthymia are vulnerable to secondary episodes of major depression (sometimes referred to as double depression). Adjustment disorder with depressed mood is a mood disturbance appearing as a psychological response to an identifiable event or stressor, in which the resulting emotional or behavioral symptoms are significant but do not meet the criteria for a major depressive episode. Bipolar disorder, previously known as manic-depressive disorder, is a condition in which depressive phases alternate with periods of mania or hypomania. Although depression is currently categorized as a separate disorder, there is ongoing debate because individuals diagnosed with major depression often experience some hypomanic symptoms, indicating a mood disorder continuum.
A 2008 meta-analysis found that behavioral interventions, such as interpersonal therapy, are effective at preventing new onset depression. Because such interventions appear to be most effective when delivered to individuals or small groups, it has been suggested that they may be able to reach their large target audience most efficiently through the Internet. However, an earlier meta-analysis found preventive programs with a competence-enhancing component to be superior to behaviorally oriented programs overall, and found behavioral programs to be particularly unhelpful for older people, for whom social support programs were uniquely beneficial. Additionally, the programs that best prevented depression comprised more than eight sessions, each lasting between 60 and 90 minutes; were provided by a combination of lay and professional workers; had a high-quality research design; reported attrition rates; and had a well-defined intervention. The "Coping with Depression" course (CWD) is claimed to be the most successful of psychoeducational interventions for the treatment and prevention of depression (both for its adaptability to various populations and its results), with a risk reduction of 38% in major depression and an efficacy as a treatment comparing favorably to other psychotherapies.
The three most common treatments for depression are psychotherapy, medication, and electroconvulsive therapy. Psychotherapy is the treatment of choice for people under 18, while electroconvulsive therapy is only used as a last resort. Care is usually given on an outpatient basis, while treatment in an inpatient unit is considered if there is a significant risk to self or others. A significant number of recent studies have indicated that physical exercise has beneficial effects.
Treatment options are much more limited in developing countries, where access to mental health staff, medication, and psychotherapy is often difficult. Development of mental health services is minimal in many countries; depression is viewed as a phenomenon of the developed world despite evidence to the contrary, and not as an inherently life-threatening condition.
Psychotherapy can be delivered, to individuals or groups, by mental health professionals, including psychotherapists, psychiatrists, psychologists, clinical social workers, counselors, and psychiatric nurses. With more complex and chronic forms of depression, a combination of medication and psychotherapy may be used. In people under 18, according to the National Institute for Health and Clinical Excellence, medication should only be offered in conjunction with a psychological therapy, such as CBT, interpersonal therapy, or family therapy. Psychotherapy has been shown to be effective in older people. Successful psychotherapy appears to reduce the recurrence of depression even after it has been terminated or replaced by occasional booster sessions.
The most studied form of psychotherapy for depression is CBT, thought to work by teaching clients to learn a set of useful cognitive and behavioral skills. Earlier research suggested that CBT was not as effective as antidepressant medication; however, research beginning in the mid-1990s suggested that CBT could perform as well or better than antidepressants in patients with moderate to severe depression. CBT may be effective in depressed adolescents, although its effects on severe episodes might not be definitively known. Combining fluoxetine with CBT appeared to bring no additional benefit, or, at the most, only marginal benefit. Several variables predict success for cognitive behavior therapy in adolescents: higher levels of rational thoughts, less hopelessness, fewer negative thoughts, and fewer cognitive distortions. CBT is particularly beneficial in preventing relapse. Several variants of cognitive behavior therapy have been used in depressed patients, most notably rational emotive behavior therapy, and more recently mindfulness-based cognitive therapy.
Interpersonal psychotherapy focuses on the social and interpersonal triggers that may cause depression. The therapy takes a structured course with a set number of weekly sessions (often 12) that focus on relationships with others. Therapy can be used to foster interpersonal skills that allow people to communicate more effectively and to reduce stress.
Psychoanalysis is a school of thought, founded by Sigmund Freud, which emphasizes the resolution of unconscious mental conflicts. Psychoanalytic techniques are used by some practitioners to treat clients presenting with major depression. A more widely practiced, eclectic technique, called psychodynamic psychotherapy, is loosely based on psychoanalysis and has an additional social and interpersonal focus. In a meta-analysis of three controlled trials of Short Psychodynamic Supportive Psychotherapy, this modification was found to be as effective as medication for mild to moderate depression.
Logotherapy, a form of existential psychotherapy developed by Austrian psychiatrist Viktor Frankl, addresses the filling of an "existential vacuum" associated with feelings of futility and meaninglessness. It is posited that this type of psychotherapy may be useful for depression in older adolescents.
The effects of prescription antidepressants can be comparable to those of psychotherapy, although more patients cease medication than cease psychotherapy, most likely due to adverse effects from the medication.
To find the most effective antidepressant medication with minimal side effects, the dosages can be adjusted, and if necessary, combinations of different classes of antidepressants can be tried. Response rates to the first antidepressant administered range from 50–75%, and it can take at least six to eight weeks from the start of medication to remission, when the patient is back to their normal self. Antidepressant medication treatment is usually continued for 16 to 20 weeks after remission, to minimize the chance of recurrence, and even up to 1 year of continuation is recommended. People with chronic depression may need to take medication indefinitely to avoid relapse.
Selective serotonin reuptake inhibitors (SSRIs), such as sertraline, escitalopram, fluoxetine, paroxetine, and citalopram are the primary medications prescribed owing to their effectiveness, relatively mild side effects, and because they are less toxic in overdose than other antidepressants. Patients who do not respond to one SSRI can be switched to another, and this results in improvement in almost 50% of cases. Another option is to switch to the atypical antidepressant bupropion. Venlafaxine, an antidepressant with a different mechanism of action, may be modestly more effective than SSRIs. However, venlafaxine is not recommended in the UK as a first-line treatment because of evidence suggesting its risks may outweigh benefits, and it is specifically discouraged in children and adolescents. For adolescent depression, fluoxetine and escitalopram are the two recommended choices. Antidepressants have not been found to be beneficial in children. Any antidepressant can cause low serum sodium levels (also called hyponatremia); nevertheless, it has been reported more often with SSRIs. It is not uncommon for SSRIs to cause or worsen insomnia; the sedating antidepressant mirtazapine can be used in such cases.
Monoamine oxidase inhibitors, an older class of antidepressants, have been plagued by potentially life-threatening dietary and drug interactions. They are still used only rarely, although newer and better tolerated agents of this class have been developed.
The terms "refractory depression" and "treatment-resistant depression" are used to describe cases that do not respond to adequate courses of at least two antidepressants. In many major studies, only about 35% of patients respond well to medical treatment. It may be difficult for a doctor to decide when someone has treatment-resistant depression or whether the problem is due to coexisting disorders, which are common among patients with major depression.
A doctor may add a medication with a different mode of action to bolster the effect of an antidepressant in cases of treatment resistance. Medication with lithium salts has been used to augment antidepressant therapy in those who have failed to respond to antidepressants alone. Furthermore, lithium dramatically decreases the suicide risk in recurrent depression. Addition of a thyroid hormone, triiodothyronine may work as well as lithium, even in patients with normal thyroid function. Addition of atypical antipsychotics when the patient has not responded to an antidepressant is also known to increase the effectiveness of antidepressant drugs, albeit offset by increased side effects.
Comparative efficacy of medication and psychotherapy
Two recent meta-analyses of clinical trial results submitted to the FDA concluded that antidepressants are statistically superior to placebo but their overall effect is low-to-moderate. In that respect they often did not exceed the National Institute for Health and Clinical Excellence criteria for a "clinically significant" effect. In particular, the effect size was very small for moderate depression but increased with severity reaching "clinical significance" for very severe depression. These result were consistent with the earlier clinical studies in which only patients with severe depression benefited from either psychotherapy or treatment with an antidepressant, imipramine, more than from the placebo treatment. Despite obtaining similar results, the authors argued about their interpretation. One author concluded that there "seems little evidence to support the prescription of antidepressant medication to any but the most severely depressed patients, unless alternative treatments have failed to provide benefit." The other author agreed that "antidepressant 'glass' is far from full" but disagreed "that it is completely empty". He pointed out that the first-line alternative to medication is psychotherapy, which does not have superior efficacy.
Antidepressants in general are as effective as psychotherapy for major depression, and this conclusion holds true for both severe and mild forms of MDD. In contrast, medication gives better results for dysthymia. The subgroup of SSRIs may be slightly more efficacious than psychotherapy. On the other hand, significantly more patients drop off from the antidepressant treatment than from psychotherapy, likely because of the side effects of antidepressants. Successful psychotherapy appears to prevent the recurrence of depression even after it has been terminated or replaced by occasional "booster" sessions. The same degree of prevention can be achieved by continuing antidepressant treatment.
Black box warning
A black box warning was introduced in the United States in 2007 on SSRI and other antidepressant medications due to increased risk of suicide in patients younger than 24 years old.
Electroconvulsive therapy (ECT) is a procedure whereby pulses of electricity are sent through the brain via two electrodes, usually one on each temple, to induce a seizure while the patient is under a short general anaesthetic. Hospital psychiatrists may recommend ECT for cases of severe major depression which have not responded to antidepressant medication or, less often, psychotherapy or supportive interventions. ECT can have a quicker effect than antidepressant therapy and thus may be the treatment of choice in emergencies such as catatonic depression where the patient has stopped eating and drinking, or where a patient is severely suicidal. ECT is probably more effective than pharmacotherapy for depression in the immediate short-term, although a landmark community-based study found much lower remission rates in routine practice. Used on its own the relapse rate within the first six months is very high; early studies put the rate at around 50%, while a more recent controlled trial found rates of 84% even with placebos. The early relapse rate may be reduced by the use of psychiatric medications or further ECT (although the latter is not recommended by some authorities) but remains high. Common initial adverse effects from ECT include short and long-term memory loss, disorientation and headache. Although objective psychological testing shows memory disturbance after ECT has mostly resolved by one month post treatment, ECT remains a controversial treatment, and debate on the extent of cognitive effects and safety continues.
Physical exercise is recommended by U.K. health authorities, and a systematic review of 23 studies indicated a "large clinical effect". Among these, three studies employing intention to treat analysis and other bias-reducing measures were inconclusive. Its benefits are most statistically significant in mild to moderate forms of depression and anxiety.
St John's wort is available over-the-counter as a herbal remedy in some parts of the world; however, the evidence of its effectiveness for the treatment of major depression is varying and confusing. Its safety can be compromised by inconsistency in pharmaceutical quality and in the amounts of active ingredient in different preparations. Further, it interacts with numerous prescribed medicines including antidepressants, and it can reduce the effectiveness of hormonal contraception.
The efficacy of omega-3 fatty acids for major depression is unclear, with controlled studies and meta-analyses supporting both positive and negative conclusions.
Reviews of short-term clinical trials of S-adenosylmethionine (SAMe) indicate that it may be effective in treating major depression in adults. A 2002 review reported that tryptophan and 5-hydroxytryptophan appear to be better than placebo, but found most of the evidence in their favor to be of poor quality and inconclusive.
Other somatic treatments
Repetitive transcranial magnetic stimulation (rTMS) applies powerful magnetic fields to the brain from outside the head. Multiple controlled studies support the use of this method in treatment-resistant depression; it has been approved for this indication in Europe, Canada, Australia, and the US. rTMS appeared similarly effective for both uncomplicated depression and depression resistant to medication; however, it was inferior to ECT in a side-by-side randomized trial.
Vagus nerve stimulation was approved by the FDA in the United States in 2005 for use in treatment-resistant depression, although it failed to show short-term benefit in the only large double-blind trial when used as an adjunct on treatment-resistant patients; a 2008 systematic review concluded that despite the promising results reported mainly in open studies, further clinical trials are needed to confirm its efficacy in major depression.
Major depressive episodes often resolve over time whether or not they are treated. Outpatients on a waiting list show a 10–15% reduction in symptoms within a few months, with approximately 20% no longer meeting the full criteria for a depressive disorder. The median duration of an episode has been estimated to be 23 weeks, with the highest rate of recovery in the first three months.
Studies have shown that 80% of those suffering from their first major depressive episode will suffer from at least 1 more during their life, with a lifetime average of 4 episodes. Other general population studies indicate around half those who have an episode (whether treated or not) recover and remain well, while the other half will have at least one more, and around 15% of those experience chronic recurrence. Studies recruiting from selective inpatient sources suggest lower recovery and higher chronicity, while studies of mostly outpatients show that nearly all recover, with a median episode duration of 11 months. Around 90% of those with severe or psychotic depression, most of whom also meet criteria for other mental disorders, experience recurrence.
Recurrence is more likely if symptoms have not fully resolved with treatment. Current guidelines recommend continuing antidepressants for four to six months after remission to prevent relapse. Evidence from many randomized controlled trials indicates continuing antidepressant medications after recovery can reduce the chance of relapse by 70% (41% on placebo vs. 18% on antidepressant). The preventive effect probably lasts for at least the first 36 months of use.
Depressed individuals have a shorter life expectancy than those without depression, in part because depressed patients are at risk of dying by suicide. However, they also have a higher rate of dying from other causes, being more susceptible to medical conditions such as heart disease. Up to 60% of people who commit suicide have a mood disorder such as major depression, and the risk is especially high if a person has a marked sense of hopelessness or has both depression and borderline personality disorder. The lifetime risk of suicide associated with a diagnosis of major depression in the US is estimated at 3.4%, which averages two highly disparate figures of almost 7% for men and 1% for women (although suicide attempts are more frequent in women). The estimate is substantially lower than a previously accepted figure of 15% which had been derived from older studies of hospitalized patients.
Disability-adjusted life year
for unipolar depressive disorders per 100,000 inhabitants in 2002.
no data ≤ 600 600-700 700-800 800-900 900-1000 1000-1100 1100-1200 1200-1300 1300-1400 1400-1500 1500-1600 ≥ 1600
Depression is a major cause of morbidity worldwide. Lifetime prevalence varies widely, from 3% in Japan to 17% in the US. In most countries the number of people who would suffer from depression during their lives falls within an 8–12% range. In North America the probability of having a major depressive episode within a year-long period is 3–5% for males and 8–10% for females. Population studies have consistently shown major depression to be about twice as common in women as in men, although it is unclear why this is so, and whether factors unaccounted for are contributing to this. The relative increase in occurrence is related to pubertal development rather than chronological age, reaches adult ratios between the ages of 15 and 18, and appears associated with psychosocial more than hormonal factors.
People are most likely to suffer their first depressive episode between the ages of 30 and 40, and there is a second, smaller peak of incidence between ages 50 and 60. The risk of major depression is increased with neurological conditions such as stroke, Parkinson's disease, or multiple sclerosis and during the first year after childbirth. It is also more common after cardiovascular illnesses, and is related more to a poor outcome than to a better one. Studies conflict on the prevalence of depression in the elderly, but most data suggest there is a reduction in this age group.
Depression is often associated with unemployment and poverty. Major depression is currently the leading cause of disease burden in North America and other high-income countries, and the fourth-leading cause worldwide. In the year 2030, it is predicted to be the second-leading cause of disease burden worldwide after HIV, according to the World Health Organization. Delay or failure in seeking treatment after relapse, and the failure of health professionals to provide treatment, are two barriers to reducing disability.
Major depression frequently co-occurs with other psychiatric problems. The 1990–92 National Comorbidity Survey (US) reports that 51% of those with major depression also suffer from lifetime anxiety. Anxiety symptoms can have a major impact on the course of a depressive illness, with delayed recovery, increased risk of relapse, greater disability and increased suicide attempts. American neuroendocrinologist Robert Sapolsky similarly argues that the relationship between stress, anxiety, and depression could be measured and demonstrated biologically. There are increased rates of alcohol and drug abuse and particularly dependence, and around a third of individuals diagnosed with ADHD develop comorbid depression. Post-traumatic stress disorder and depression often co-occur.
Depression and pain often co-occur. One or more pain symptoms is present in 65% of depressed patients, and anywhere from five to 85% of patients with pain will be suffering from depression, depending on the setting; there is a lower prevalence in general practice, and higher in specialty clinics. The diagnosis of depression is often delayed or missed, and the outcome worsens.
Depression is also associated with a 1.5- to 2-fold increased risk of cardiovascular disease, independent of other known risk factors, and is itself linked directly or indirectly to risk factors such as smoking and obesity. People with major depression are less likely to follow medical recommendations for treating cardiovascular disorders, which further increases their risk. In addition, cardiologists may not recognize underlying depression that complicates a cardiovascular problem under their care.
The Ancient Greek physician Hippocrates described a syndrome of melancholia as a distinct disease with particular mental and physical symptoms; he characterized all "fears and despondencies, if they last a long time" as being symptomatic of the ailment. It was a similar but far broader concept than today's depression; prominence was given to a clustering of the symptoms of sadness, dejection, and despondency, and often fear, anger, delusions and obsessions were included.
The term depression itself was derived from the Latin verb deprimere, "to press down". From the 14th century, "to depress" meant to subjugate or to bring down in spirits. It was used in 1665 in English author Richard Baker's Chronicle to refer to someone having "a great depression of spirit", and by English author Samuel Johnson in a similar sense in 1753. The term also came in to use in physiology and economics. An early usage referring to a psychiatric symptom was by French psychiatrist Louis Delasiauve in 1856, and by the 1860s it was appearing in medical dictionaries to refer to a physiological and metaphorical lowering of emotional function. Since Aristotle, melancholia had been associated with men of learning and intellectual brilliance, a hazard of contemplation and creativity. The newer concept abandoned these associations and through the 19th century, became more associated with women.
Although melancholia remained the dominant diagnostic term, depression gained increasing currency in medical treatises and was a synonym by the end of the century; German psychiatrist Emil Kraepelin may have been the first to use it as the overarching term, referring to different kinds of melancholia as depressive states.
Sigmund Freud likened the state of melancholia to mourning in his 1917 paper Mourning and Melancholia. He theorized that objective loss, such as the loss of a valued relationship through death or a romantic break-up, results in subjective loss as well; the depressed individual has identified with the object of affection through an unconscious, narcissistic process called the libidinal cathexis of the ego. Such loss results in severe melancholic symptoms more profound than mourning; not only is the outside world viewed negatively, but the ego itself is compromised. The patient's decline of self-perception is revealed in his belief of his own blame, inferiority, and unworthiness. He also emphasized early life experiences as a predisposing factor. Meyer put forward a mixed social and biological framework emphasizing reactions in the context of an individual's life, and argued that the term depression should be used instead of melancholia. The first version of the DSM (DSM-I, 1952) contained depressive reaction and the DSM-II (1968) depressive neurosis, defined as an excessive reaction to internal conflict or an identifiable event, and also included a depressive type of manic-depressive psychosis within Major affective disorders.
In the mid-20th century, researchers theorized that depression was caused by a chemical imbalance in neurotransmitters in the brain, a theory based on observations made in the 1950s of the effects of reserpine and isoniazid in altering monoamine neurotransmitter levels and affecting depressive symptoms.
The term Major depressive disorder was introduced by a group of US clinicians in the mid-1970s as part of proposals for diagnostic criteria based on patterns of symptoms (called the "Research Diagnostic Criteria", building on earlier Feighner Criteria), and was incorporated in to the DSM-III in 1980. To maintain consistency the ICD-10 used the same criteria, with only minor alterations, but using the DSM diagnostic threshold to mark a mild depressive episode, adding higher threshold categories for moderate and severe episodes. The ancient idea of melancholia still survives in the notion of a melancholic subtype.
The new definitions of depression were widely accepted, albeit with some conflicting findings and views. There have been some continued empirically based arguments for a return to the diagnosis of melancholia. There has been some criticism of the expansion of coverage of the diagnosis, related to the development and promotion of antidepressants and the biological model since the late 1950s.
Even today, people's conceptualizations of depression vary widely, both within and among cultures. "Because of the lack of scientific certainty," one commentator has observed, "the debate over depression turns on questions of language. What we call it—'disease,' 'disorder,' 'state of mind'—affects how we view, diagnose, and treat it." There are cultural differences in the extent to which serious depression is considered an illness requiring personal professional treatment, or is an indicator of something else, such as the need to address social or moral problems, the result of biological imbalances, or a reflection of individual differences in the understanding of distress that may reinforce feelings of powerlessness, and emotional struggle.
The diagnosis is less common in some countries, such as China. It has been argued that the Chinese traditionally deny or somatize emotional depression (although since the early 1980s the Chinese denial of depression may have modified drastically). Alternatively, it may be that Western cultures reframe and elevate some expressions of human distress to disorder status. Australian professor Gordon Parker and others have argued that the Western concept of depression "medicalizes" sadness or misery. Similarly, Hungarian-American psychiatrist Thomas Szasz and others argue that depression is a metaphorical illness that is inappropriately regarded as an actual disease. There has also been concern that the DSM, as well as the field of descriptive psychiatry that employs it, tends to reify abstract phenomena such as depression, which may in fact be social constructs. American archetypal psychologist James Hillman writes that depression can be healthy for the soul, insofar as "it brings refuge, limitation, focus, gravity, weight, and humble powerlessness." Hillman argues that therapeutic attempts to eliminate depression echo the Christian theme of resurrection, but have the unfortunate effect of demonizing a soulful state of being.
Historical figures were often reluctant to discuss or seek treatment for depression due to social stigma about the condition, or due to ignorance of diagnosis or treatments. Nevertheless, analysis or interpretation of letters, journals, artwork, writings or statements of family and friends of some historical personalities has led to the presumption that they may have had some form of depression. People who may have had depression include English author Mary Shelley, American-British writer Henry James, and American president Abraham Lincoln. Some well-known contemporary people with possible depression include Canadian songwriter Leonard Cohen and American playwright and novelist Tennessee Williams. Some pioneering psychologists, such as Americans William James and John B. Watson, dealt with their own depression.
There has been a continuing discussion of whether neurological disorders and mood disorders may be linked to creativity, a discussion that goes back to Aristotelian times. British literature gives many examples of reflections on depression. English philosopher John Stuart Mill experienced a several-months-long period of what he called "a dull state of nerves", when one is "unsusceptible to enjoyment or pleasurable excitement; one of those moods when what is pleasure at other times, becomes insipid or indifferent". He quoted English poet Samuel Taylor Coleridge's "Dejection" as a perfect description of his case: "A grief without a pang, void, dark and drear, / A drowsy, stifled, unimpassioned grief, / Which finds no natural outlet or relief / In word, or sigh, or tear." English writer Samuel Johnson used the term "the black dog" in the 1780s to describe his own depression, and it was subsequently popularized by depression sufferer former British Prime Minister Sir Winston Churchill.
Social stigma of major depression is widespread, and contact with mental health services reduces this only slightly. Public opinions on treatment differ markedly to those of health professionals; alternative treatments are held to be more helpful than pharmacological ones, which are viewed poorly. In the UK, the Royal College of Psychiatrists and the Royal College of General Practitioners conducted a joint Five-year Defeat Depression campaign to educate and reduce stigma from 1992 to 1996; a MORI study conducted afterwards showed a small positive change in public attitudes to depression and treatment.
- ^ a b c d e "Depression" (PDF). National Institute of Mental Health (NIMH). http://www.nimh.nih.gov/health/publications/depression/nimhdepression.pdf. Retrieved 2008-09-07.
- ^ Hays RD, Wells KB, Sherbourne CD (1995). "Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses". Archives of General Psychiatry 52 (1): 11–19. PMID 7811158.
- ^ a b c d e f American Psychiatric Association 2000a, p. 349
- ^ American Psychiatric Association 2000a, p. 412
- ^ a b Delgado PL and Schillerstrom J (2009). "Cognitive Difficulties Associated With Depression: What Are the Implications for Treatment?". Psychiatric Times 26 (3). http://www.psychiatrictimes.com/display/article/10168/1387631.
- ^ a b c d American Psychiatric Association 2000a, p. 350
- ^ Patel V, Abas M, Broadhead J (February 2001). (fulltext) "Depression in developing countries: Lessons from Zimbabwe". BMJ 322 (7284): 482–84. doi:10.1136/bmj.322.7284.482+[subscription+required] (inactive 2009-09-23). http://www.bmj.com/cgi/content/full/322/7284/482 (fulltext). Retrieved 2008-10-05.
- ^ American Psychiatric Association 2000a, p. 354
- ^ Brunsvold GL, Oepen G (2008). "Comorbid Depression in ADHD: Children and Adolescents". Psychiatric Times 25 (10). http://www.psychiatrictimes.com/adhd/article/10168/1286863.
- ^ Faculty of Psychiatry of Old Age, NSW Branch, RANZCP; Kitching D Raphael B (2001) (PDF). Consensus Guidelines for Assessment and Management of Depression in the Elderly. North Sydney, New South Wales: NSW Health Department. pp. 2. ISBN 0-7347-33410. http://www.health.nsw.gov.au/pubs/2001/pdf/depression_elderly.pdf.
- ^ Yohannes AM and Baldwin RC (2008). "Medical Comorbidities in Late-Life Depression". Psychiatric Times 25 (14). http://www.psychiatrictimes.com/depression/article/10168/1358135.
- ^ Department of Health and Human Services (1999). "The fundamentals of mental health and mental illness" (PDF). Mental Health: A Report of the Surgeon General. http://www.surgeongeneral.gov/library/mentalhealth/pdfs/c2.pdf. Retrieved 2008-11-11.
- ^ a b Caspi A, Sugden K, Moffitt TE (2003). "Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene". Science 301 (5631): 386–89. doi:10.1126/science.1083968. PMID 12869766.
- ^ Haeffel GJ; Getchell M; Koposov RA; Yrigollen CM; DeYoung CG; af Klinteberg B; et al. (2008). "Association between polymorphisms in the dopamine transporter gene and depression: Evidence for a gene-environment interaction in a sample of juvenile detainees" (PDF). Psychological Science. http://www.nd.edu/~ghaeffel/Resources/Haeffel%20et%20al.,%202008.pdf. Retrieved 2008-11-11.
- ^ Slavich GM (September 2004). "Deconstructing depression: A diathesis-stress perspective (Opinion)". APS Observer. http://www.psychologicalscience.org/observer/getArticle.cfm?id=1640. Retrieved 2008-11-11.
- ^ Kendler KS, Gatz M, Gardner CO, Pedersen NL (January 2006). "A Swedish national twin study of lifetime major depression". American Journal of Psychiatry 163 (1): 109–14. doi:10.1176/appi.ajp.163.1.109. PMID 16390897.
- ^ Schuckit MA, Tipp JE, Bergman M, Reich W, Hesselbrock VM, Smith TL (July 1997). "Comparison of induced and independent major depressive disorders in 2,945 alcoholics". Am J Psychiatry 154 (7): 948–57. PMID 9210745. http://ajp.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=9210745.
- ^ a b c Professor Heather Ashton (2002). "Benzodiazepines: How They Work and How to Withdraw". http://www.benzo.org.uk/manual/bzcha03.htm.
- ^ Barlow 2005, p. 226
- ^ Shah N, Eisner T, Farrell M, Raeder C (July/August 1999). "An overview of SSRIs for the treatment of depression" (PDF). Journal of the Pharmacy Society of Wisconsin. http://www.pswi.org/professional/pharmaco/depression.pdf. Retrieved 2008-11-10.
- ^ a b Nutt DJ (2008). "Relationship of neurotransmitters to the symptoms of major depressive disorder". Journal of Clinical Psychiatry 69 Suppl E1: 4–7. PMID 18494537.
- ^ Hirschfeld RM (2000). "History and evolution of the monoamine hypothesis of depression". Journal of Clinical Psychiatry 61 Suppl 6: 4–6. PMID 10775017.
- ^ Delgado PL (2000). "Depression: The case for a monoamine deficiency". Journal of Clinical Psychiatry 61 Suppl 6: 7–11. PMID 10775018.
- ^ Lacasse J, Leo J (2005). "Serotonin and depression: A disconnect between the advertisements and the scientific literature". PLoS Med 2 (12): e392. doi:10.1371/journal.pmed.0020392.g001. PMID 16268734. PMC 1277931. http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0020392. Retrieved 2008-10-30.
- ^ Videbech, P and Ravnkilde (2004). "Hippocampal volume and depression: A meta-analysis of MRI studies". American Journal of Psychiatry 161 (11): 1957–66.. doi:10.1176/appi.ajp.161.11.1957. PMID 15514393.
- ^ Videbech, P (1997). "MRI findings in patients with affective disorder: a meta-analysis". Acta Psychiatrica Scandinavica 96 (3): 157–68. doi:10.1111/j.1600-0447.1997.tb10146.x. PMID 9296545.
- ^ Herrmann LL, Le Masurier M, Ebmeier KP (2008). "White matter hyperintensities in late life depression: a systematic review". Journal of Neurology, Neurosurgery, and Psychiatry 79 (6): 619–24. doi:10.1136/jnnp.2007.124651. PMID 17717021.
- ^ Mayberg H (July 6, 2007). "Brain pathway may underlie depression". Scientific American 17 (4): 26–31. http://www.sciam.com/article.cfm?id=brain-pathway-may-underlie-depression. Retrieved 2008-09-13.
- ^ Sheline YI, Gado MH, Kraemer HC (2003). "Untreated depression and hippocampal volume loss". American Journal of Psychiatry 160 (8): 1516–18. doi:10.1176/appi.ajp.160.8.1516. PMID 12900317.
- ^ Duman RS, Heninger GR, Nestler EJ (1997). "A molecular and cellular theory of depression". Archives of General Psychiatry 54 (7): 597–606. PMID 9236543.
- ^ Drevets WC, Savitz J, Trimble M (August 2008). "The subgenual anterior cingulate cortex in mood disorders". CNS Spectrums 13 (8): 663–81. PMID 18704022.
- ^ Sen S, Duman R, Sanacora G (September 2008). "Serum brain-derived neurotrophic factor, depression, and antidepressant medications: Meta-analyses and implications". Biological Psychiatry 64 (6): 527–32. doi:10.1016/j.biopsych.2008.05.005. PMID 18571629.
- ^ Monteleone P (2001). (abstract) "Endocrine disturbances and psychiatric disorders". Current Opinion in Psychiatry (Lippincott Williams & Wilkins, Inc.) 14 (6): 605–10. ISSN 0951–7367. http://www.co-psychiatry.com/pt/re/copsych/abstract.00001504-200111000-00020.htm;jsessionid=JWdDsz1T6hhjhpsR47xrbhpTjhxhpdS64Yh8QzptbqR1rrNkmVfF!1600976923!181195628!8091!-1 (abstract).
- ^ a b c Adrien J. (October 2003). "Neurobiological bases for the relation between sleep and depression". Sleep Medicine Review 6 (5): 341–51. PMID 12531125.
- ^ a b Terman M (December 2007). "Evolving applications of light therapy". Sleep Medicine Review 11 (6): 497–507. doi:10.1016/j.smrv.2007.06.003. PMID 17964200.
- ^ Benedetti F, Barbini B, Colombo C, Smeraldi E (October 2007). "Chronotherapeutics in a psychiatric ward". Sleep Medicine Review 11 (6): 509–22. doi:10.1016/j.smrv.2007.06.004. PMID 17689120.
- ^ a b Cutter WJ, Norbury R, Murphy DG (July 2003). "Oestrogen, brain function, and neuropsychiatric disorders". Journal of Neurology, Neurosurgery and Psychiatry 74 (7): 837–40. doi:10.1136/jnnp.74.7.837. PMID 12810759. PMC 1738534. http://jnnp.bmj.com/cgi/pmidlookup?view=long&pmid=12810759.
- ^ Douma, S.L, Husband, C., O’Donnell, M.E., Barwin, B.N., Woodend A.K. (2005). "Estrogen-related Mood Disorders Reproductive Life Cycle Factors". Advances in Nursing Science 28 (4): 364–375. PMID 16292022.
- ^ Lasiuk, GC and Hegadoren, KM (2007). "The Effects of Estradiol on Central Serotonergic Systems and Its Relationship to Mood in Women". Biological Research for Nursing (2007), 9 (2): 147–160. doi:10.1177/1099800407305600. PMID 17909167.
- ^ Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW (2008). "From inflammation to sickness and depression: when the immune system subjugates the brain". Nat Rev Neurosci 9 (1): 46–56. doi:10.1038/nrn2297. PMID 18073775.
- ^ a b c Raphael B (2000). "Unmet Need for Prevention". in Andrews G, Henderson S (eds). Unmet Need in Psychiatry:Problems, Resources, Responses. Cambridge University Press. pp. 138–39. ISBN 0-521-66229-X.
- ^ PMID
- ^ Sadock 2002, p. 541
- ^ Dein, Simon (2006). "Religion, spirituality and depression: implications for research and treatment" (PDF). Primary Care and Community Psychiatry 11 (2): 67–72. doi:10.1185/135525706X121110. http://www.librapharm.com/headeradmin/upload/0178web2.pdf. Retrieved 2008-11-21.
- ^ Moreira-Almeida, A; Neto, FL; Koenig, HG (September 2006). "Religiousness and mental health: a review". Rev. Bras. Psiquiatr. 28 (3): 242–50. PMID 16924349. http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462006000300018&lng=en&nrm=iso&tlng=en.
- ^ Warman DM, Beck AT (June 2003). "About treatment and supports: Cognitive behavioral therapy". National Alliance on Mental Illness (NAMI) website. http://www.nami.org/Template.cfm?Section=About_Treatments_and_Supports&template=/ContentManagement/ContentDisplay.cfm&ContentID=7952. Retrieved 2008-10-17.
- ^ Beck 1987, pp. 10–15
- ^ Beck 1987, p. 3
- ^ Seligman, M (1975). "Depression". Helplessness: On depression, development and death. San Francisco, CA, USA: WH Freeman. pp. 75–106. ISBN 0716707519.
- ^ a b Barlow 2005, pp. 230–32
- ^ Pinto A, Francis G (1993). "Cognitive correlates of depressive symptoms in hospitalized adolescents". Adolescence 28 (111): 661–72. PMID 8237551.
- ^ Bandura A (1998). "Self-Efficacy". in Friedman H. Encyclopedia of mental health. San Diego: Academic Press. ISBN 0122266765. http://www.des.emory.edu/mfp/BanEncy.html. Retrieved 2008-08-17.
- ^ Brown GW, Harris TO (2001) . Social Origins of Depression: A Study of Psychiatric Disorder in Women. Routledge. ISBN 0-415-20268-X.
- ^ Hinrichsen GA, Emery EE (2006). "Interpersonal factors and late-life depression" (Subscription required). Clinical Psychology: Science and Practice 12 (3): 264–75. doi:10.1093/clipsy/bpi027. http://www3.interscience.wiley.com/journal/118706655/abstract?CRETRY=1&SRETRY=0.
- ^ a b Carhart-Harris RL, Mayberg HS, Malizia AL, Nutt D (2008). "Mourning and melancholia revisited: Correspondences between principles of Freudian metapsychology and empirical findings in neuropsychiatry". Annals of General Psychiatry 7: 9. doi:10.1186/1744-859X-7-9. PMID 18652673.
- ^ a b Freud, S (1984). "Mourning and Melancholia". in Richards A (ed.). 11.On Metapsychology: The Theory of Psycholoanalysis. Aylesbury, Bucks: Pelican. pp. 245–69. ISBN 0-14-021740-1.
- ^ a b c d Radden, J (March 2003). "Is this dame melancholy? Equating today's depression and past melancholia". Philosophy, Psychiatry, & Psychology 10 (1): 37–52. doi:10.1353/ppp.2003.0081. http://muse.jhu.edu/journals/philosophy_psychiatry_and_psychology/v010/10.1radden01.html.
- ^ Frankl VE (2000). Man's search for ultimate meaning. New York, NY, USA: Basic Books. pp. 139–40. ISBN 0738203548.
- ^ Geppert CMA (May 2006). "Damage control". Psychiatric Times. http://www.psychiatrictimes.com/display/article/10168/51281. Retrieved 2008-11-08.
- ^ May 1994, p. 133
- ^ Boeree, CG (1998). "Abraham Maslow: Personality Theories" (PDF). Psychology Department, Shippensburg University. http://www.social-psychology.de/do/pt_maslow.pdf. Retrieved 2008-10-27.
- ^ Maslow A (1971). The Farther Reaches of Human Nature. New York, NY, USA: Viking Books. pp. 318. ISBN 0670308536.
- ^ Heim C, Newport DJ, Mletzko T, Miller AH, Nemeroff CB (July 2008). "The link between childhood trauma and depression: insights from HPA axis studies in humans". Psychoneuroendocrinology 33 (6): 693–710. doi:10.1016/j.psyneuen.2008.03.008. PMID 18602762.
- ^ Kessler, RC (1997). "The effects of stressful life events on depression". Annual revue of Psychology 48: 191–214. doi:10.1146/annurev.psych.48.1.191. PMID 9046559.
- ^ Kendler, KS; Hettema, JM; Butera, F; Gardner, CO; Prescott, CA (2003). "Life event dimensions of loss, humiliation, entrapment, and danger in the prediction of onsets of major depression and generalized anxiety". Archives of General Psychiatry 60 (8): 789–796. doi:10.1001/archpsyc.60.8.789. PMID 12912762.
- ^ Slavich GM, Thornton T, Torres LD, Monroe SM, Gotlib IH (2009). "Targeted rejection predicts hastened onset of major depression". Journal of Social and Clinical Psychology 28: 223–243. doi:10.1521/jscp.2009.28.2.223.
- ^ Monroe SM, Slavich GM, Torres LD, Gotlib IH (2007). "Major life events and major chronic difficulties are differentially associated with history of major depressive episodes". Journal of Abnormal Psychology 116 (1): 116–124. doi:10.1037/0021-843X.116.1.116. PMID 17324022.
- ^ Sadock 2002, p. 540
- ^ Vilhjalmsson R (1993). "Life stress, social support and clinical depression: A reanalysis of the literature". Social Science & Medicine 37 (3): 331–42. doi:10.1016/0277-9536(93)90264-5. PMID 8356482.
- ^ Kim D. (2008) Blues from the Neighborhood? Neighborhood Characteristics and Depression. Epidemiol Rev Aug 27 PMID 18753674
- ^ Bonde JP (July 2008). "Psychosocial factors at work and risk of depression: A systematic review of the epidemiological evidence". Journal of Occupational and Environmental Medicine 65 (7): 438–45. doi:10.1136/oem.2007.038430. PMID 18417557.
- ^ Panksepp J, Moskal JR, Panksepp JB, Kroes RA (December 2002). "Comparative approaches in evolutionary psychology: Molecular neuroscience meets the mind" (PDF). Neuroendocrinology Letters 23 (Supplement 4): 105–15. PMID 12496741. http://www.nel.edu/pdf_w/23s4/NEL231002R11_Panksepp_.pdf.
- ^ Sloman L, Gilbert P, Hasey G (April 2003). "Evolved mechanisms in depression: The role and interaction of attachment and social rank in depression". Journal of Affective Disorders 74 (2): 107–21. doi:10.1016/S0165-0327(02)00116-7. PMID 12706512. http://linkinghub.elsevier.com/retrieve/pii/S0165032702001167.
- ^ Tooby, J, Cosmides, L (2005) (PDF). Conceptual foundations of evolutionary psychology. In D. M. Buss (Ed.), The Handbook of Evolutionary Psychology. Hoboken, NJ: Wiley & Sons. pp. 5–67. http://www.psych.ucsb.edu/research/cep/papers/bussconceptual05.pdf.
- ^ Carey TJ (2005). "Evolution, depression and counselling". Counselling Psychology Quarterly 18 (3): 215–22. doi:10.1080/09515070500304508. http://www.ingentaconnect.com/content/routledg/ccpq/2005/00000018/00000003/art00005.
- ^ Mashman, RC (1997). "An evolutionary view of psychic misery". Journal of Social Behaviour & Personality 12: 979–99. ISSN 0886-1641.
- ^ Berber MJ (November 1999). "Pharmacological treatment of depression. Consulting with Dr Oscar" (PDF). Can Fam Physician 45: 2663–8. PMID 10587774. PMC 2328680. http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2328680&blobtype=pdf.
- ^ Fergusson DM, Boden JM, Horwood LJ (March 2009). "Tests of causal links between alcohol abuse or dependence and major depression". Arch. Gen. Psychiatry 66 (3): 260–6. doi:10.1001/archgenpsychiatry.2008.543. PMID 19255375. http://archpsyc.ama-assn.org/cgi/pmidlookup?view=long&pmid=19255375.
- ^ Falk DE, Yi HY, Hilton ME (April 2008). "Age of onset and temporal sequencing of lifetime DSM-IV alcohol use disorders relative to comorbid mood and anxiety disorders". Drug Alcohol Depend 94 (1-3): 234–45. doi:10.1016/j.drugalcdep.2007.11.022. PMID 18215474. PMC 2386955. http://linkinghub.elsevier.com/retrieve/pii/S0376-8716(07)00499-1.
- ^ Schuckit MA, Smith TL, Danko GP (November 2007). "A comparison of factors associated with substance-induced versus independent depressions". J Stud Alcohol Drugs 68 (6): 805–12. PMID 17960298.
- ^ Semple, David; Roger Smyth, Jonathan Burns, Rajan Darjee, Andrew McIntosh (2007) . "13". Oxford Handbook of Psychiatry. United Kingdom: Oxford University Press. p. 540. ISBN 0198527837.
- ^ Collier, Judith; Longmore, Murray (2003). "4". in Scally, Peter. Oxford Handbook of Clinical Specialties (6 ed.). Oxford University Press. p. 366. ISBN 978-0198525189.
- ^ Ashton CH (March 1995). "Protracted Withdrawal From Benzodiazepines: The Post-Withdrawal Syndrome". Psychiatric Annals (benzo.org.uk) 25 (3): 174–179. http://www.benzo.org.uk/pha-1.htm.
- ^ Professor Heather Ashton (2004). "Protracted Withdrawal Symptoms From Benzodiazepines". Comprehensive Handbook of Drug & Alcohol Addiction. http://www.benzo.org.uk/pws04.htm.
- ^ Kaufmann IM (September 1, 1993). "Rural psychiatric services. A collaborative model". Canadian Family Physician 39: 1957–61. PMID 8219844.
- ^ "Call for action over Third World depression". BBC News (Health). British Broadcasting Corporation (BBC). November 1, 1999. http://news.bbc.co.uk/1/hi/health/492941.stm. Retrieved 2008-10-11.
- ^ a b Sharp LK, Lipsky MS (September 2002). "Screening for depression across the lifespan: a review of measures for use in primary care settings". American family physician 66 (6): 1001–8. PMID 12358212.
- ^ Gilbody, S; House, AO; Sheldon, TA (2005). "Screening and case finding instruments for depression". Cochrane Database of Systematic Reviews (4): CD002792. doi:10.1002/14651858.CD002792.pub2. PMID 16235301. http://www.cochrane.org/reviews/en/ab002792.html.
- ^ Cepoiu, M.; Mccusker, J.; Cole, G.; Sewitch, M.; Belzile, E.; Ciampi, A. (Jan 2008). "Recognition of Depression by Non-psychiatric Physicians—A Systematic Literature Review and Meta-analysis". Journal of General Internal Medicine 23 (1): 25. doi:10.1007/s11606-007-0428-5. ISSN 0884-8734. PMID 17968628.
- ^ Mitchell, A. J.; Vaze, A.; Rao, S. (2009). "Clinical diagnosis of depression in primary care: a meta-analysis". The Lancet 374: 609–619. doi:10.1016/S0140-6736(09)60879-5.
- ^ Dale J, Sorour E, Milner G (2008). "Do psychiatrists perform appropriate physical investigations for their patients? A review of current practices in a general psychiatric inpatient and outpatient setting". Journal of Mental Health 17 (3): 293–98. doi:10.1080/09638230701498325.
- ^ Orengo C, Fullerton G, Tan R (2004). "Male depression: A review of gender concerns and testosterone therapy". Geriatrics 59 (10): 24–30. PMID 15508552.
- ^ Reid LM, Maclullich AM (2006). "Subjective memory complaints and cognitive impairment in older people". Dementia and geriatric cognitive disorders 22 (5–6): 471–85. doi:10.1159/000096295. PMID 17047326.
- ^ Katz IR (1998). "Diagnosis and treatment of depression in patients with Alzheimer's disease and other dementias". The Journal of clinical psychiatry 59 Suppl 9: 38–44. PMID 9720486.
- ^ Wright SL, Persad C (December 2007). "Distinguishing between depression and dementia in older persons: Neuropsychological and neuropathological correlates". Journal of geriatric psychiatry and neurology 20 (4): 189–98. doi:10.1177/0891988707308801. PMID 18004006.
- ^ Sadock 2002, p. 108
- ^ Sadock 2002, p. 260
- ^ "ICD-10:". www.who.int. http://www.who.int/classifications/apps/icd/icd10online/?gf30.htm+f33. Retrieved 2008-11-08.
- ^ Sadock 2002, p. 288
- ^ American Psychiatric Association 2000a, p. xxix
- ^ American Psychiatric Association 2000a, p. 345
- ^ "Mood (affective) disorders". ICD-10, Chapter V, Mental and behavioural disorders. World Health Organization (WHO). 2004. http://www.who.int/classifications/apps/icd/icd10online2005/fr-icd.htm?gf30.htm. Retrieved 2008-10-19.
- ^ American Psychiatric Association 2000a, p. 372
- ^ Parker 1996, p. 173
- ^ American Psychiatric Association 2000a, p. 352
- ^ Wakefield JC, Schmitz MF, First MB, Horwitz AV (April 2007). "Extending the bereavement exclusion for major depression to other losses: Evidence from the National Comorbidity Survey". Archives of General Psychiatry 64 (4): 433–40. doi:10.1001/archpsyc.64.4.433. PMID 17404120. http://archpsyc.ama-assn.org/cgi/content/full/64/4/433. Lay summary – The Washington Post (2007-04-03).
- ^ Kendler KS, Gardner CO (February 1, 1998). "Boundaries of major depression: An evaluation of DSM-IV criteria". American Journal of Psychiatry 155 (2): 172–77. PMID 9464194. http://ajp.psychiatryonline.org/cgi/content/full/155/2/172.
- ^ a b Sadock 2002, p. 552
- ^ American Psychiatric Association 2000a, p. 778
- ^ Carta, MG; Altamura, AC; Hardoy, MC; Pinna, F; Medda, S; Dell'osso, L; Carpiniello, B; Angst, J (2003). "Is recurrent brief depression an expression of mood spectrum disorders in young people?". European Archives of Psychiatry and Clinical Neuroscience 253 (3): 149–53. doi:10.1007/s00406-003-0418-5. PMID 12904979.
- ^ Rapaport MH, Judd LL, Schettler PJ (2002). "A descriptive analysis of minor depression". American Journal of Psychiatry 159 (4): 637–43. doi:10.1176/appi.ajp.159.4.637. PMID 11925303.
- ^ a b American Psychiatric Association 2000a, p. 355
- ^ American Psychiatric Association 2000a, pp. 419–20
- ^ American Psychiatric Association 2000a, pp. 421–22
- ^ American Psychiatric Association 2000a, pp. 417–18
- ^ "ICD-10:". www.who.int. http://www.who.int/classifications/apps/icd/icd10online/?gf50.htm+f530. Retrieved 2008-11-06.
- ^ Nonacs, Ruta M (December 4, 2007). "Postpartum depression". eMedicine. http://www.emedicine.com/med/topic3408.htm. Retrieved 2008-10-30.
- ^ American Psychiatric Association 2000a, p. 425
- ^ Akiskal HS, Benazzi F (May 2006). "The DSM-IV and ICD-10 categories of recurrent [major] depressive and bipolar II disorders: Evidence that they lie on a dimensional spectrum". Journal of Affective Disorders 92 (1): 45–54. doi:10.1016/j.jad.2005.12.035. PMID 16488021.
- ^ Cuijpers P, van Straten A, Smit F, Mihalopoulos C, Beekman A (October 2008). "Preventing the onset of depressive disorders: a meta-analytic review of psychological interventions". Am J Psychiatry 165 (10): 1272–80. doi:10.1176/appi.ajp.2008.07091422. PMID 18765483.
- ^ Christensen H; Griffiths KM. (2002). "The prevention of depression using the Internet" (PDF). Medical Journal of Australia. http://www.mja.com.au/public/issues/177_07_071002/chr10370_fm.pdf. Retrieved 2009-04-02.
- ^ Jané-Llopis E; Hosman C; Jenkins R; Anderson P. (2003). "Predictors of efficacy in depression prevention programmes" (PDF). British Journal of Psychiatry. http://bjp.rcpsych.org/cgi/reprint/183/5/384.pdf. Retrieved 2009-04-02.
- ^ Cuijpers P, Muñoz RF, Clarke GN, Lewinsohn PM (July 2009). "Psychoeducational treatment and prevention of depression: the "Coping with Depression" course thirty years later.". Clinical Psychology Review 29 (5): 449–458. doi:10.1016/j.cpr.2009.04.005. PMID pmid19450912. http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VB8-4W3HX9Y-1&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=911e35bd8c903da7281fe66eb6d3069f.
- ^ Patel, V; Araya, R; Bolton, P (April 2004). (fulltext) "Editorial: Treating depression in the developing world" (Subscription required). Tropical Medicine & International Health 9 (5): 539–41. doi:10.1111/j.1365-3156.2004.01243.x. PMID 15117296. http://www3.interscience.wiley.com/cgi-bin/fulltext/118806521/HTMLSTART?CRETRY=1&SRETRY=0 (fulltext). Retrieved 2008-10-05.
- ^ Thase, ME (1999). "When are psychotherapy and pharmacotherapy combinations the treatment of choice for major depressive disorder?". Psychiatric Quarterly 70 (4): 333–46. doi:10.1023/A:1022042316895. PMID 10587988.
- ^ NICE (2005). NICE guidelines: Depression in children and adolescents. London: NICE. pp. 5. ISBN 1-84629-074-0.
- ^ Wilson KC, Mottram PG, Vassilas CA (January 2008). "Psychotherapeutic treatments for older depressed people". Cochrane Database of Systematic Reviews 23 (1): CD004853. doi:10.1002/14651858.CD004853.pub2. PMID 18254062.
- ^ Cuijpers P, van Straten A, Smit F (December 2006). "Psychological treatment of late-life depression: a meta-analysis of randomized controlled trials". International Journal of Geriatric Psychiatry 21 (12): 1139–49. doi:10.1002/gps.1620. PMID 16955421.
- ^ Dobson KS (June 1989). "A meta-analysis of the efficacy of cognitive therapy for depression". J Consult Clin Psychol 57 (3): 414–9. doi:10.1037/0022-006X.57.3.414. PMID 2738214.
- ^ Roth, Anthony; Fonagy, Peter (2005) . What Works for Whom? Second Edition: A Critical Review of Psychotherapy Research. Guilford Press. pp. 78. ISBN 159385272X.
- ^ Klein, VR; Walker, PN (2008). "Review: Cognitive behavioural therapy for adolescents with depression". Evidence-Based Mental Health 11 (3): 76. doi:10.1136/ebmh.11.3.76. PMID 18669678. http://ebmh.bmj.com/cgi/content/full/11/3/76. Retrieved 2008-11-27.
- ^ Harrington R, Whittaker J, Shoebridge P, Campbell F (May 1998). "Systematic review of efficacy of cognitive behaviour therapies in childhood and adolescent depressive disorder". BMJ 325 (7358): 229–30. doi:10.1136/bmj.325.7358.229. PMID 9596592.
- ^ Goodyer I, Dubicka B, Wilkinson P (July 2007). "Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: Randomised controlled trial". BMJ 335 (7611): 142. doi:10.1136/bmj.39224.494340.55. PMID 17556431.
- ^ Goodyer IM, Dubicka B, Wilkinson P (May 2008). "A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial". Health Technology Assessment 12 (14): 1–80. PMID 18462573. http://www.hta.ac.uk/execsumm/summ1214.htm.
- ^ Domino ME, Burns BJ, Silva SG (May 2008). "Cost-effectiveness of treatments for adolescent depression: Results from TADS". American Journal of Psychiatry 165 (5): 588–96. doi:10.1176/appi.ajp.2008.07101610. PMID 18413703.
- ^ Becker, SJ (2008). "Cognitive-Behavioral Therapy for Adolescent Depression: Processes of Cognitive Change". Psychiatric Times 25 (14). http://www.psychiatrictimes.com/depression/article/10168/1357884.
- ^ Almeida, AM; Lotufo Neto, F (2003). "Cognitive-behavioral therapy in prevention of depression relapses and recurrences: a review". Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) 25 (4): 239–44. doi:/S1516-44462003000400011 (inactive 2009-11-14). PMID 15328551.
- ^ Paykel, ES (2007). "Cognitive therapy in relapse prevention in depression.". The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 10 (1): 131–6. doi:10.1017/S1461145706006912. PMID 16787553.
- ^ Beck 1987, p. 10
- ^ Coelho HF, Canter PH, Ernst E (December 2007). "Mindfulness-based cognitive therapy: Evaluating current evidence and informing future research". Journal of Consulting and Clinical Psychology 75 (6): 1000–05. doi:10.1037/0022-006X.75.6.1000. PMID 18085916.
- ^ Weissman MM, Markowitz JC, Klerman GL (2000). Comprehensive Guide to Interpersonal Psychotherapy. New York: Basic Books. ISBN 0-465-09566-6. (Page number needed)
- ^ Dworetzky J (1997). Psychology. Pacific Grove, CA, USA: Brooks/Cole Pub. Co. pp. 602. ISBN 0-314-20412-1.
- ^ Doidge N, Simon B, Lancee WJ (2002). "Psychoanalytic patients in the US, Canada, and Australia: II. A DSM-III-R validation study". Journal of the American Psychoanalytic Association 50 (2): 615–27. doi:10.1177/00030651020500021101. PMID 12206545.
- ^ Barlow 2005, p. 20
- ^ de Maat S, Dekker J, Schoevers R (June 2007). "Short Psychodynamic Supportive Psychotherapy, antidepressants, and their combination in the treatment of major depression: A mega-analysis based on three Randomized Clinical Trials". Depression and Anxiety 25 (7): 565. doi:10.1002/da.20305. PMID 17557313.
- ^ Blair RG (October 2004). "Helping older adolescents search for meaning in depression". Journal of Mental Health Counseling. http://findarticles.com/p/articles/mi_hb1416/is_4_26/ai_n29132028/pg_1?tag=artBody;col1. Retrieved 2008-11-06.
- ^ Cuijpers P, van Straten A, van Oppen P, Andersson G (November 2008). "Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies". Journal of Clinical Psychiatry 69 (11): 1675–85. doi:10.4088/JCP.v69n1102. PMID 18945396.
- ^ a b Wheeler, DC; Morgan, R; Thomas, DM; Seed, M; Rees, A; Moore, RH (April 2000). "Practice Guideline for the Treatment of Patients With Major Depressive Disorder (Second Edition)". Transplant international : official journal of the European Society for Organ Transplantation (American Psychiatric Association) 9 (3): 1–78. doi:10.1176/appi.books.9780890423363.48690. http://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=MDD2e_05-15-06.
- ^ Thase, M (December 2006). "Preventing relapse and recurrence of depression: a brief review of therapeutic options". CNS spectrums 11 (12 Suppl 15): 12–21. PMID 17146414.
- ^ a b c Royal Pharmaceutical Society of Great Britain 2008, p. 204
- ^ Whooley MA, Simon GE (2000). (abstract) "Managing Depression in Medical Outpatients". New England Journal of Medicine 343 (26): 1942–50. doi:10.1056/NEJM200012283432607. PMID 11136266. http://content.nejm.org/cgi/content/short/343/26/1942 (abstract). Retrieved 2008-11-11.
- ^ Zisook S, Rush AJ, Haight BR, Clines DC, Rockett CB (2006). "Use of bupropion in combination with serotonin reuptake inhibitors". Biological Psychiatry 59 (3): 203–10. doi:10.1016/j.biopsych.2005.06.027. PMID 16165100.
- ^ Rush AJ, Trivedi MH, Wisniewski SR (2006). "Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression". New England Journal of Medicine 354 (12): 1231–42. doi:10.1056/NEJMoa052963. PMID 16554525.
- ^ Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ (2006). "Medication augmentation after the failure of SSRIs for depression". New England Journal of Medicine 354 (12): 1243–52. doi:10.1056/NEJMoa052964. PMID 16554526.
- ^ Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC (December 2007). "Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents". Biological Psychiatry 62 (11): 1217–27. doi:10.1016/j.biopsych.2007.03.027. PMID 17588546.
- ^ Prof Gordon Duff (31 May 2006.). "The Medicines and Healthcare products Regulatory Agency (MHRA)". http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&dDocName=CON2023842&RevisionSelectionMethod=LatestReleased.
- ^ a b Depression in children and young people: Identification and management in primary, community and secondary care. NHS National Institute for Health and Clinical Excellence. September 2005.
- ^ Mayers AG, Baldwin DS (December 2005). "Antidepressants and their effect on sleep". Human Psychopharmacology 20 (8): 533–59. doi:10.1002/hup.726. PMID 16229049.
- ^ "Lexapro Prescribing Information for the U.S." (PDF). Forest Laboratories. March 2009. http://www.frx.com/pi/lexapro_pi.pdf. Retrieved 2009-04-09.
- ^ Tsapakis EM, Soldani F, Tondo L, Baldessarini RJ (July 2008). "Efficacy of antidepressants in juvenile depression: meta-analysis". Br J Psychiatry 193 (1): 10–7. doi:10.1192/bjp.bp.106.031088. PMID 18700212.
- ^ Palmer B, Gates J, Lader M (2003). "Causes and Management of Hyponatremia". The Annals of Pharmacotherapy 37 (11): 1694–702. doi:10.1345/aph.1D105. PMID 14565794.
- ^ Guaiana G., Barbui C., Hotopf M. (July 2007). "Amitriptyline for depression.". Cochrane Database Syst Review 18 (3): 11–7. doi:10.1002/14651858.CD004186.pub2. PMID 9597346.
- ^ Anderson IM (April 2000). "Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability". Journal of Affective Disorders 58 (1): 19–36. doi:10.1016/S0165-0327(99)00092-0. PMID 10760555. http://linkinghub.elsevier.com/retrieve/pii/S0165-0327(99)00092-0.
- ^ Krishnan KR (2007). "Revisiting monoamine oxidase inhibitors". Journal of Clinical Psychiatry 68 Suppl 8: 35–41. PMID 17640156.
- ^ Wijeratne, Chanaka, Sachdev, Perminder (2008). "Treatment-resistant depression: Critique of current approaches". Australian and New Zealand Journal of Psychiatry 42 (9): 751–62. doi:10.1080/00048670802277206. PMID 18696279.
- ^ Barbee JG (2008). "Treatment-Resistant Depression: Advances in Assessment". Psychiatric Times 25 (10). http://www.psychiatrictimes.com/depression/article/10168/1285073.
- ^ Valenstein M, McCarthy JF, Austin KL, Greden JF, Young EA, Blow FC (2006). "What happened to lithium? Antidepressant augmentation in clinical settings". American Journal of Psychiatry 163 (7): 1219–25. doi:10.1176/appi.ajp.163.7.1219. PMID 16816227.
- ^ Bschor T, Bauer M (2006). "Efficacy and mechanisms of action of lithium augmentation in refractory major depression". Current Pharmaceudical Design 12 (23): 2985–92. doi:10.2174/138161206777947650. PMID 16918427.
- ^ Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ (March 2007). "Lithium treatment reduces suicide risk in recurrent major depressive disorder". Journal of Clinical Psychiatry 68 (3): 380–83. doi:10.4088/JCP.v68n0304. PMID 17388706.
- ^ Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, Alpert JE, Warden D, Luther JF, Niederehe G, Lebowitz B, Shores-Wilson K, Rush AJ (2006). "A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: A STAR*D report". American Journal of Psychiatry 163 (9): 1519–30. doi:10.1176/appi.ajp.163.9.1519. PMID 16946176.
- ^ Bender KJ (2008-02-01). "Evidence Grows for Value of Antipsychotics as Antidepressant Adjuncts - Psychiatric Times". Psychiatric Times. http://www.psychiatrictimes.com/display/article/10168/1147436. Retrieved 2008-08-06.
- ^ a b Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (February 2008). "Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration". PLoS Med. 5 (2): e45. doi:10.1371/journal.pmed.0050045. PMID 18303940. PMC 2253608. http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0050045&ct=1.
- ^ Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (January 2008). "Selective publication of antidepressant trials and its influence on apparent efficacy". N. Engl. J. Med. 358 (3): 252–60. doi:10.1056/NEJMsa065779. PMID 18199864.
- ^ Elkin I, Shea MT, Watkins JT, Imber SD, Sotsky SM, Collins JF, Glass DR, Pilkonis PA, Leber WR, Docherty JP (1989). "National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments". Archives of General Psychiatry 46 (11): 971–82; discussion 983. PMID 2684085.
- ^ Elkin I, Gibbons RD, Shea MT, Sotsky SM, Watkins JT, Pilkonis PA, Hedeker D (1995). "Initial severity and differential treatment outcome in the National Institute of Mental Health Treatment of Depression Collaborative Research Program". Journal of Consulting and Clinical Psychology 63 (5): 841–47. doi:10.1037/0022-006X.63.5.841. PMID 7593878.
- ^ Sotsky SM, Glass DR, Shea MT, Pilkonis PA, Collins JF, Elkin I, Watkins JT, Imber SD, Leber WR, Moyer J (1991). "Patient predictors of response to psychotherapy and pharmacotherapy: Findings in the NIMH Treatment of Depression Collaborative Research Program". American Journal of Psychiatry 148 (8): 997–1008. PMID 1853989.
- ^ Turner EH, Rosenthal R (March 2008). "Efficacy of antidepressants". BMJ 336 (7643): 516–7. doi:10.1136/bmj.39510.531597.80. PMID 18319297.
- ^ a b c Cuijpers P, van Straten A, van Oppen P, Andersson G (August 2008). "Are Psychological and Pharmacologic Interventions Equally Effective in the Treatment of Adult Depressive Disorders? A Meta-Analysis of Comparative Studies". Journal of Clinical Psychiatry: e1–e11. http://www.psychiatrist.com/abstracts/abstracts.asp?abstract=oap/ej08r04112.htm.
- ^ a b c Imel ZE, Malterer MB, McKay KM, Wampold BE (October 2008). "A meta-analysis of psychotherapy and medication in unipolar depression and dysthymia". J Affect Disord 110 (3): 197–206. doi:10.1016/j.jad.2008.03.018. PMID 18456340.
- ^ "FDA Proposes New Warnings About Suicidal Thinking, Behavior in Young Adults Who Take Antidepressant Medications". FDA. 2007-05-02. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01624.html. Retrieved 2008-05-29.
- ^ a b American Psychiatric Association (April 2000b). "Practice guideline for the treatment of patients with major depressive disorder". American Journal of Psychiatry 157 (Supp 4): 1–45. PMID 10767867. http://www.guideline.gov/summary/summary.aspx?doc_id=2605#s23.
- ^ UK ECT Review Group (March 2003). "Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis". Lancet 361 (9360): 799–808. doi:10.1016/S0140-6736(03)12705-5. PMID 12642045.
- ^ Prudic J, Olfson M, Marcus SC, Fuller RB, Sackeim HA (2004). "Effectiveness of electroconvulsive therapy in community settings". Biological Psychiatry 55 (3): 301–12. doi:10.1016/j.biopsych.2003.09.015. PMID 14744473.
- ^ Bourgon LN, Kellner CH (March 2000). "Relapse of depression after ECT: a review". The journal of ECT 16 (1): 19–31. doi:10.1097/00124509-200003000-00003. PMID 10735328. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1095-0680&volume=16&issue=1&spage=19.
- ^ Sackeim HA, Haskett RF, Mulsant BH (March 2001). "Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: A randomized controlled trial". JAMA: Journal of the American Medical Association 285 (10): 1299–307. doi:10.1001/jama.285.10.1299. PMID 11255384. http://jama.ama-assn.org/cgi/content/full/285/10/1299.
- ^ Tew JD, Mulsant BH, Haskett RF, Joan P, Begley AE, Sackeim HA (2007). "Relapse during continuation pharmacotherapy after acute response to ECT: A comparison of usual care versus protocolized treatment". Annals of Clinical Psychiatry 19 (1): 1–4. doi:10.1080/10401230601163360. PMID 17453654.
- ^ Frederikse M, Petrides G, Kellner C (March 2006). "Continuation and maintenance electroconvulsive therapy for the treatment of depressive illness: a response to the National Institute for Clinical Excellence report". The journal of ECT 22 (1): 13–7. doi:10.1097/00124509-200603000-00003. PMID 16633200. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?an=00124509-200603000-00003.
- ^ National Institute for Clinical Excellence (2003) (PDF). Guidance on the use of electroconvulsive therapy. London: National Institute for Health and Clinical Excellence. ISBN 1-84257-282-2. http://www.nice.org.uk/nicemedia/pdf/59ectfullguidance.pdf.
- ^ Kellner CH, Knapp RG, Petrides G (December 2006). "Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: A multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE)". Archives of General Psychiatry 63 (12): 1337–44. doi:10.1001/archpsyc.63.12.1337. PMID 17146008. http://archpsyc.ama-assn.org/cgi/content/full/63/12/1337.
- ^ Barlow 2005, p. 239
- ^ Ingram A, Saling MM, Schweitzer I (March 2008). "Cognitive Side Effects of Brief Pulse Electroconvulsive Therapy: A Review". Journal of ECT 24 (1): 3–9. doi:10.1097/YCT.0b013e31815ef24a. PMID 18379328.
- ^ Reisner AD (December 2003). "The electroconvulsive therapy controversy: evidence and ethics" (PDF). Neuropsychology review 13 (4): 199–219. doi:10.1023/B:NERV.0000009484.76564.58. PMID 15000226. http://www.kluweronline.com/art.pdf?issn=1040-7308&volume=13&page=199.
- ^ "Management of depression in primary and secondary care" (PDF). National Clinical Practice Guideline Number 23. National Institute for Health and Clinical Excellence. 2007. http://www.nice.org.uk/nicemedia/pdf/CG023fullguideline.pdf. Retrieved 2008-11-04.
- ^ Mead GE, Morley W, Campbell P, Greig CA, McMurdo M, Lawlor DA (2008). "Exercise for depression". Cochrane database of systematic reviews (Online) (4): CD004366. doi:10.1002/14651858.CD004366.pub3. PMID 18843656.
- ^ Martinsen EW (October 2008). "Physical activity in the prevention and treatment of anxiety and depression.". Nordic Journal of Psychiatry 62 (S47): 25–29. doi:10.1080/08039480802315640. PMID 18752115.
- ^ "St. John's Wort and Depression". NCCAM Health Information. Archived from the original on 2007-10-11. http://web.archive.org/web/20071011030548/http://nccam.nih.gov/health/stjohnswort/sjwataglance.htm. Retrieved 2008-10-13.
- ^ Linde K, Mulrow CD, Berner M, Egger M (2005). "St John's wort for depression". Cochrane Database Systematic Reviews (2): CD000448. doi:10.1002/14651858.CD000448.pub2. PMID 15846605.
- ^ Sarino LV, Dang KH, Dianat N (2007). "Drug interaction between oral contraceptives and St. John's Wort: appropriateness of advice received from community pharmacists and health food store clerks". J Am Pharm Assoc (2003) 47 (1): 42–7. doi:10.1331/1544-3126.96.36.199.Sarino. PMID 17338474.
- ^ Richardson AJ (February 2008). "n-3 Fatty acids and mood: the devil is in the detail". Br. J. Nutr. 99 (2): 221–3. doi:10.1017/S0007114507824123. PMID 17919344.
- ^ Freeman MP, Hibbeln JR, Wisner KL, Davis JM, Mischoulon D, Peet M, Keck PE, Marangell LB, Richardson AJ, Lake J, Stoll AL (2006). "Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry". Journal of Clinical Psychiatry 67 (12): 1954–67. doi:10.4088/JCP.v67n1217. PMID 17194275.
- ^ Ross BM, Seguin J, Sieswerda LE (2007). "Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?". Lipids Health Dis 6: 21. doi:10.1186/1476-511X-6-21. PMID 17877810. PMC 2071911. http://www.lipidworld.com/content/6//21.
- ^ Appleton KM, Hayward RC, Gunnell D (December 2006). "Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials". Am. J. Clin. Nutr. 84 (6): 1308–16. PMID 17158410. http://www.ajcn.org/cgi/pmidlookup?view=long&pmid=17158410.
- ^ Rogers PJ, Appleton KM, Kessler D (February 2008). "No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial". Br. J. Nutr. 99 (2): 421–31. doi:10.1017/S0007114507801097. PMID 17956647.
- ^ Williams AL, Girard C, Jui D, Sabina A, Katz DL (2005). "S-adenosylmethionine (SAMe) as treatment for depression: a systematic review" (PDF). Clin Invest Med 28 (3): 132–9. PMID 16021987. http://www.csci-scrc.org/cim/cim_jun2005.pdf. Retrieved 2008-12-04.
- ^ Shaw K, Turner J, Del Mar C (2002). "Tryptophan and 5-hydroxytryptophan for depression". Cochrane Database of Systematic Reviews (1): CD003198. doi:10.1002/14651858.CD003198. PMID 11869656.
- ^ Marangell LB, Martinez M, Jurdi RA, Zboyan H (September 2007). "Neurostimulation therapies in depression: A review of new modalities". Acta Psychiatrica Scandinavica 116 (3): 174–81. doi:10.1111/j.1600-0447.2007.01033.x. PMID 17655558.
- ^ a b Schutter DJ (April 2008). "Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs: A meta-analysis". Psychological Medicine 39 (1): 1–11. doi:10.1017/S0033291708003462. PMID 18447962.
- ^ DeNoon, Daniel J. (October 8, 2008). "FDA OKs TMS Depression Device: Brain-Stimulating Device Cleared for Depression Treatment After 1 Drug Failure". WebMD. WebMD. http://www.webmd.com/depression/news/20081008/fda-oks-tms-depression-device. Retrieved 10 November 2008.
- ^ Eranti S, Mogg A, Pluck G (January 2007). "A randomized, controlled trial with 6-month follow-up of repetitive transcranial magnetic stimulation and electroconvulsive therapy for severe depression". Am J Psychiatry 164 (1): 73–81. doi:10.1176/appi.ajp.164.1.73. PMID 17202547.
- ^ "VNS Therapy System - P970003s050". Device Approvals and Clearances. FDA. 12 August 2005. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm078532.htm. Retrieved 11 November 2009.
- ^ Rush AJ, Marangell LB, Sackeim HA (September 2005). "Vagus nerve stimulation for treatment-resistant depression: A randomized, controlled acute phase trial". Biological Psychiatry 58 (5): 347–54. doi:10.1016/j.biopsych.2005.05.025. PMID 16139580.
- ^ Daban C, Martinez-Aran A, Cruz N, Vieta E (September 2008). "Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review". J Affect Disord 110 (1-2): 1–15. doi:10.1016/j.jad.2008.02.012. PMID 18374988. http://linkinghub.elsevier.com/retrieve/pii/S0165-0327(08)00095-5.
- ^ Posternak MA, Miller I (2001). "Untreated short-term course of major depression: A meta-analysis of outcomes from studies using wait-list control groups". Journal of Affective Disorders 66 (2–3): 139–46. doi:10.1016/S0165-0327(00)00304-9. PMID 11578666.
- ^ Posternak MA, Solomon DA, Leon AC (2006). "The naturalistic course of unipolar major depression in the absence of somatic therapy". Journal of Nervous and Mental Disease 194 (5): 324–29. doi:10.1097/01.nmd.0000217820.33841.53. PMID 16699380.
- ^ Fava GA, Park SK, Sonino N (November 2006). "Treatment of recurrent depression.". Expert Review of Neurotherapeutics 6 (11): 1735–1740. doi:10.1586/14737188.8.131.525. PMID 17144786.
- ^ Limosin F, Mekaoui L, Hautecouverture S (November 2007). "Stratégies thérapeutiques prophylactiques dans la dépression unipolaire [Prophylactic treatment for recurrent major depression]". La Presse Médicale 36 (11-C2): 1627–1633. doi:10.1016/j.lpm.2007.03.032. PMID 17555914.
- ^ Eaton WW, Shao H, Nestadt G (May 2008). "Population-based study of first onset and chronicity in major depressive disorder". Archives of General Psychiatry 65 (5): 513–20. doi:10.1001/archpsyc.65.5.513. PMID 18458203.
- ^ Holma KM, Holma IA, Melartin TK (February 2008). "Long-term outcome of major depressive disorder in psychiatric patients is variable". Journal of Clinical Psychiatry 69 (2): 196–205. doi:10.4088/JCP.v69n0205. PMID 18251627.
- ^ Kanai T, Takeuchi H, Furukawa TA (July 2003). "Time to recurrence after recovery from major depressive episodes and its predictors". Psychological Medicine 33 (5): 839–45. doi:10.1017/S0033291703007827. PMID 12877398.
- ^ Geddes JR, Carney SM, Davies C (February 2003). "Relapse prevention with antidepressant drug treatment in depressive disorders: A systematic review". Lancet 361 (9358): 653–61. doi:10.1016/S0140-6736(03)12599-8. PMID 12606176.
- ^ Cassano P, Fava M (October 2002). "Depression and public health: an overview". J Psychosom Res 53 (4): 849–57. doi:10.1016/S0022-3999(02)00304-5. PMID 12377293. http://linkinghub.elsevier.com/retrieve/pii/S0022399902003045.
- ^ Rush AJ (2007). "The varied clinical presentations of major depressive disorder". The Journal of clinical psychiatry 68 (Supplement 8): 4–10. PMID 17640152.
- ^ a b Alboni P, Favaron E, Paparella N, Sciammarella M, Pedaci M (April 2008). "Is there an association between depression and cardiovascular mortality or sudden death?". Journal of cardiovascular medicine (Hagerstown, Md.) 9 (4): 356–62. doi:10.2459/JCM.0b013e3282785240 (inactive 2009-09-23). PMID 18334889.
- ^ Barlow 2005, pp. 248–49
- ^ Blair-West GW, Mellsop GW (2001). "Major depression: Does a gender-based down-rating of suicide risk challenge its diagnostic validity?". Australian and New Zealand Journal of Psychiatry 35 (3): 322–28. doi:10.1046/j.1440-1614.2001.00895.x. PMID 11437805.
- ^ Oquendo MA, Bongiovi-Garcia ME, Galfalvy H (January 2007). "Sex differences in clinical predictors of suicidal acts after major depression: a prospective study". The American journal of psychiatry 164 (1): 134–41. doi:10.1176/appi.ajp.164.1.134. PMID 17202555.
- ^ Bostwick, JM; Pankratz, VS (2000). "Affective disorders and suicide risk: A reexamination". American Journal of Psychiatry 157 (12): 1925–32. doi:10.1176/appi.ajp.157.12.1925. PMID 11097952. http://ajp.psychiatryonline.org/cgi/content/full/157/12/1925.
- ^ "Mortality and Burden of Disease Estimates for WHO Member States in 2002" (xls). World Health Organization. 2002. http://www.who.int/entity/healthinfo/statistics/bodgbddeathdalyestimates.xls.
- ^ "The world health report 2001 - Mental Health: New Understanding, New Hope". WHO website. World Health Organization. 2001. http://www.who.int/whr/2001/en/index.html. Retrieved 2008-10-19.
- ^ Andrade L, Caraveo-Anduaga JJ, Berglund P (2003). "The epidemiology of major depressive episodes: Results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys". Int J Methods Psychiatr Res 12 (1): 3–21. doi:10.1002/mpr.138. PMID 12830306.
- ^ Kessler RC, Berglund P, Demler O (2003). "The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R)". JAMA 289 (203): 3095–105. doi:10.1001/jama.289.23.3095. PMID 12813115.
- ^ Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005). "Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication". Archives of General Psychiatry 62 (6): 617–27. doi:10.1001/archpsyc.62.6.593. PMID 15939837.
- ^ Murphy JM, Laird NM, Monson RR, Sobol AM, Leighton AH (2000). "A 40-year perspective on the prevalence of depression: The Stirling County Study". Archives of General Psychiatry 57 (3): 209–15. doi:10.1001/archpsyc.57.3.209. PMID 10711905.
- ^ a b Kuehner, C (2003). "Gender differences in unipolar depression: An update of epidemiological findings and possible explanations". Acta Psychiatrica Scandinavica 108 (3): 163–74. doi:10.1034/j.1600-0447.2003.00204.x. PMID 12890270.
- ^ Eaton WW, Anthony JC, Gallo J (1997). "Natural history of diagnostic interview schedule/DSM-IV major depression. The Baltimore Epidemiologic Catchment Area follow-up". Archives of General Psychiatry 54 (11): 993–99. PMID 9366655.
- ^ Rickards H (2005). "Depression in neurological disorders: Parkinson's disease, multiple sclerosis, and stroke". Journal of Neurology Neurosurgery and Psychiatry 76: i48–i52. doi:10.1136/jnnp.2004.060426. PMID 15718222. PMC 1765679. http://jnnp.bmj.com/cgi/content/full/76/suppl_1/i48.
- ^ Strik JJ, Honig A, Maes M (May 2001). "Depression and myocardial infarction: relationship between heart and mind". Progress in neuro-psychopharmacology & biological psychiatry 25 (4): 879–92. doi:10.1016/S0278-5846(01)00150-6. PMID 11383983. http://linkinghub.elsevier.com/retrieve/pii/S0278-5846(01)00150-6.
- ^ Jorm AF (January 2000). "Does old age reduce the risk of anxiety and depression? A review of epidemiological studies across the adult life span". Psychological Medicine 30 (1): 11–22. doi:10.1017/S0033291799001452. PMID 10722172.
- ^ Weich S, Lewis G (1998). (fulltext) "Poverty, unemployment, and common mental disorders: Population based cohort study". BMJ 317 (7151): 115–19. PMID 9657786. PMC 28602. http://www.bmj.com/cgi/content/full/317/7151/115 (fulltext). Retrieved 2008-09-16.
- ^ Mathers CD, Loncar D (November 2006). "Projections of global mortality and burden of disease from 2002 to 2030". PLoS Med. 3 (11): e442. doi:10.1371/journal.pmed.0030442. PMID 17132052.
- ^ Andrews G (July 2008). (fulltext) "In Review: Reducing the Burden of Depression". Canadian Journal of Psychiatry 53 (7): 420–27. PMID 18674396. http://publications.cpa-apc.org/media.php?mid=642 (fulltext). Retrieved 08-11-10.
- ^ Kessler RC, Nelson C, McGonagle KA (1996). "Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey". British Journal of Psychiatry 168 (suppl 30): 17–30. PMID 8864145.
- ^ Hirschfeld RMA (2001). [http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=181193 "The Comorbidity of Major Depression and Anxiety Disorders: Recognition and Management in Primary Care"]. Primary Care Companion to the Journal of Clinical Psychiatry 3 (6): 244–254. PMID 15014592.
- ^ Sapolsky Robert M (2004). Why zebras don't get ulcers. Henry Holt and Company, LLC. pp. 291–98. ISBN 0-8050-7369-8.
- ^ Grant BF (1995). "Comorbidity between DSM-IV drug use disorders and major depression: Results of a national survey of adults". Journal of Substance Abuse 7 (4): 481–87. doi:10.1016/0899-3289(95)90017-9. PMID 8838629.
- ^ Hallowell EM, Ratey JJ (2005). Delivered from distraction: Getting the most out of life with Attention Deficit Disorder. New York: Ballantine Books. pp. 253–55. ISBN 0-345-44231-8.
- ^ Bair, MJ; Robinson, RL; Katon, W; Kroenke, K (2003). (fulltext) "Depression and Pain Comorbidity: A Literature Review". Archives of Internal Medicine 163 (20): 2433–45. doi:10.1001/archinte.163.20.2433. PMID 14609780. http://archinte.ama-assn.org/cgi/content/full/163/20/2433 (fulltext). Retrieved 08-11-11.
- ^ Schulman J and Shapiro BA (2008). "Depression and Cardiovascular Disease: What Is the Correlation?". Psychiatric Times 25 (9). http://www.psychiatrictimes.com/depression/article/10168/1171821.
- ^ Hippocrates, Aphorisms, Section 6.23
- ^ depress. (n.d.). Online Etymology Dictionary. Retrieved June 30, 2008, from Dictionary.com
- ^ Wolpert, L. "Malignant Sadness: The Anatomy of Depression". The New York Times. http://www.nytimes.com/books/first/w/wolpert-sadness.html. Retrieved 2008-10-30.
- ^ Berrios GE (September 1988). "Melancholia and depression during the 19th century: A conceptual history". British Journal of Psychiatry 153: 298–304. doi:10.1192/bjp.153.3.298. PMID 3074848.
- ^ Davison, K (2006). "Historical aspects of mood disorders". Psychiatry 5 (4): 115–18. doi:10.1383/psyt.2006.5.4.115. http://linkinghub.elsevier.com/retrieve/pii/S1476179306700246.
- ^ Lewis, AJ (1934). "Melancholia: A historical review". Journal of Mental Science 80: 1–42. doi:10.1192/bjp.80.328.1.
- ^ American Psychiatric Association (1968). "Schizophrenia" (PDF). Diagnostic and statistical manual of mental disorders: DSM-II. Washington, DC: American Psychiatric Publishing, Inc.. pp. 36–37, 40. http://www.psychiatryonline.com/DSMPDF/dsm-ii.pdf. Retrieved 2008-08-03.
- ^ Schildkraut, JJ (1965). "The catecholamine hypothesis of affective disorders: A review of supporting evidence". American Journal of Psychiatry 122 (5): 509–22. PMID 5319766.
- ^ Spitzer RL, Endicott J, Robins E (1975). "The development of diagnostic criteria in psychiatry" (PDF). http://www.garfield.library.upenn.edu/classics1989/A1989U309700001.pdf. Retrieved 2008-11-08.
- ^ a b Philipp M, Maier W, Delmo CD (1991). "The concept of major depression. I. Descriptive comparison of six competing operational definitions including ICD-10 and DSM-III-R". European Archives of Psychiatry and Clinical Neuroscience 240 (4–5): 258–65. doi:10.1007/BF02189537. PMID 1829000. http://www.springerlink.com/content/y2460650rm747035/.
- ^ Gruenberg, A.M., Goldstein, R.D., Pincus, H.A. (2005) Classification of Depression: Research and Diagnostic Criteria: DSM-IV and ICD-10 (PDF). Wiley.com. Retrieved on October 30, 2008.
- ^ Bolwig, Tom G.; Shorter, Edward (2007). "Melancholia: Beyond DSM, beyond neurotransmitters. Proceedings of a conference, May 2006, Copenhagen, Denmark". Acta Psychiatrica Scandinavica Suppl 115 (433): 4–183. doi:10.1111/j.1600-0447.2007.00956.x. PMID 17280564. http://www3.interscience.wiley.com/journal/118538120/issue.
- ^ Fink M, Bolwig TG, Parker G, Shorter E (2007). "Melancholia: Restoration in psychiatric classification recommended". Acta Psychiatrica Scandinavica 115 (2): 89–92. doi:10.1111/j.1600-0447.2006.00943.x. PMID 17244171. http://www3.interscience.wiley.com/cgi-bin/fulltext/118538049/HTMLSTART.
- ^ Healy, David (1999). The Antidepressant Era. Cambridge, MA: Harvard University Press. pp. 42. ISBN 0-674-03958-0.
- ^ Burlingame, Michael (1997). The Inner World of Abraham Lincoln. Urbana: University of Illinois Press. ISBN 0-252-06667-7.
- ^ Maloney F (November 3, 2005). "The Depression Wars: Would Honest Abe Have Written the Gettysburg Address on Prozac?". Slate magazine. Washington Post. http://www.slate.com/id/2129377. Retrieved 2008-10-03.
- ^ Karasz A (April 2005). "Cultural differences in conceptual models of depression". Social Science in Medicine 60 (7): 1625–35. doi:10.1016/j.socscimed.2004.08.011. PMID 15652693.
- ^ Tilbury, F (2004). "There are orphans in Africa still looking for my hands': African women refugees and the sources of emotional distress". Health Sociology Review 13 (1): 54–64. doi:10.5555/hesr.2004.13.1.54 (inactive 2008-10-31). http://www.atypon-link.com/EMP/doi/abs/10.5555/hesr.2004.13.1.54. Retrieved 2008-10-03.
- ^ Parker, G; Gladstone, G; Chee, KT (2001). "Depression in the planet's largest ethnic group: The Chinese". American Journal of Psychiatry 158 (6): 857–64. PMID 11384889.
- ^ Parker, G (2007). "Is depression overdiagnosed? Yes". BMJ 335 (7615): 328. doi:10.1136/bmj.39268.475799.AD. PMID 17703040. PMC 1949440. http://www.bmj.com/cgi/content/full/335/7615/328.
- ^ Pilgrim D, Bentall R (1999). "The medicalisation of misery: A critical realist analysis of the concept of depression". Journal of Mental Health 8 (3): 261–74. doi:10.1080/09638239917580. http://www.ingentaconnect.com/content/apl/cjmh/1999/00000008/00000003/art00007.
- ^ Steibel W (Producer) (March 1998). "Is depression a disease?". Debatesdebates. http://www.szasz.com/isdepressionadiseasetranscript.html. Retrieved 2008-11-16.
- ^ Blazer DG (2005). The age of melancholy: "Major depression" and its social origins. New York, NY, USA: Routledge. ISBN 978-0415951883.
- ^ Hillman J (T Moore, Ed.) (1989). A blue fire: Selected writings by James Hillman. New York, NY, USA: Harper & Row. pp. 152–53. ISBN 0060161329.
- ^ Seymour, Miranda (2002). Mary Shelley. Grove Press. pp. 560–61. ISBN 0802139485.
- ^ "Biography of Henry James". pbs.org. http://www.pbs.org/wgbh/masterpiece/americancollection/american/genius/henry_bio.html. Retrieved 2008-08-19.
- ^ Burlingame, Michael (1997). The Inner World of Abraham Lincoln. Urbana: University of Illinois Press. ISBN 0-252-06667-7.
- ^ Pita E (2001-09-26). "An Intimate Conversation with...Leonard Cohen". http://www.webheights.net/10newsongs/press/elmunmag.htm. Retrieved 2008-10-03.
- ^ Jeste ND, Palmer BW, Jeste DV (2004). "Tennessee Williams". American Journal of Geriatric Psychiatry 12 (4): 370–75. doi:10.1176/appi.ajgp.12.4.370. PMID 15249274.
- ^ James H (Ed.) (1920). Letters of William James (Vols. 1 and 2). Montana USA: Kessinger Publishing Co. pp. 147–48. ISBN 978-0766175662.
- ^ Hergenhahn 2005, p. 311
- ^ Cohen D (1979). J. B. Watson: The Founder of Behaviourism. London, UK: Routledge & Kegan Paul. pp. 7. ISBN 0710000545.
- ^ Andreasen NC (2008). "The relationship between creativity and mood disorders". Dialogues in clinical neuroscience 10 (2): 251–5. PMID 18689294.
- ^ Simonton, DK (June 2005). "Are genius and madness related? Contemporary answers to an ancient question". Psychiatric Times 22 (7). http://www.psychiatrictimes.com/display/article/10168/52456?pageNumber=1.
- ^ Heffernan CF (1996). The melancholy muse: Chaucer, Shakespeare and early medicine. Pittsburgh, PA, USA: Duquesne University Press. ISBN 0820702625.
- ^ Mill JS (2003). "A crisis in my mental history: One stage onward" (txt). Autobiography. Project Gutenberg EBook. pp. 1826–32. ISBN 1421242001. http://www.gutenberg.org/files/10378/10378-8.txt. Retrieved 2008-08-09.
- ^ Sterba R (1947). "The 'Mental Crisis' of John Stuart Mill". Psychoanalytic Quarterly 16 (2): 271–72. http://www.pep-web.org/document.php?id=PAQ.016.0271C. Retrieved 2008-11-05.
- ^ a b "Churchill’s Black Dog?: The History of the ‘Black Dog’ as a Metaphor for Depression" (PDF). Black Dog Institute website. Black Dog Institute. January 2005. http://www.blackdoginstitute.org.au/docs/McKinlay.pdf. Retrieved 2008-08-18.
- ^ Jorm AF, Angermeyer M, Katschnig H (2000). "Public knowledge of and attitudes to mental disorders: a limiting factor in the optimal use of treatment services". in Andrews G, Henderson S (eds). Unmet Need in Psychiatry:Problems, Resources, Responses. Cambridge University Press. pp. 409. ISBN 0-521-66229-X.
- ^ Paykel ES, Tylee A, Wright A, Priest RG, Rix S, Hart D (1997). "The Defeat Depression Campaign: psychiatry in the public arena". American Journal of Psychiatry 154 (6 Suppl): 59–65. PMID 9167546.
- ^ Paykel ES, Hart D, Priest RG (1998). "Changes in public attitudes to depression during the Defeat Depression Campaign". British Journal of Psychiatry 173: 519–22. doi:10.1192/bjp.173.6.519. PMID 9926082.
- American Psychiatric Association (2000a). Diagnostic and statistical manual of mental disorders, Fourth Edition, Text Revision: DSM-IV-TR. Washington, DC: American Psychiatric Publishing, Inc.. ISBN 0890420254.
- Barlow DH; Durand VM (2005). Abnormal psychology: An integrative approach (5th ed.). Belmont, CA, USA: Thomson Wadsworth. ISBN 0534633560.
- Beck, Aaron T.; Rush J, Shaw BF, Emery G (1987) . Cognitive Therapy of depression. New York, NY, USA: Guilford Press. ISBN 0898629195.
- Freeman, Arthur; Epstein, Norman & Simon, Karen M. (1987). Depression in the Family. Haworth Press. ISBN 0866566244.
- Hergenhahn BR (2005). An Introduction to the History of Psychology (5th ed.). Belmont, CA, USA: Thomson Wadsworth. ISBN 0534554016.
- May R (1994). The discovery of being: Writings in existential psychology. New York, NY, USA: W. W. Norton & Company. ISBN 0393312402.
- Parker, Gordon; Dusan Hadzi-Pavlovic, Kerrie Eyers (1996). Melancholia: A disorder of movement and mood: A phenomenological and neurobiological review. Cambridge: Cambridge University Press. ISBN 052147275X.
- Royal Pharmaceutical Society of Great Britain (September 2008). British National Formulary (BNF 56). UK: BMJ Group and RPS Publishing. ISBN 9780853697787. http://www.bnf.org/bnf/.
- Sadock, Benjamin J.; Sadock, Virginia A. (2002). Kaplan and Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry (9th ed.). Lippincott Williams & Wilkins. ISBN 0781731836.
|Mental and behavioral disorders (F · 290–319)
(acute alcohol intoxication
, alcohol dependence
, alcoholic hallucinosis
, Alcohol withdrawal
, delirium tremens
, Korsakoff's syndrome
, alcohol abuse
) · opioids
, opioid dependency
) · sedative/hypnotic
, benzodiazepine dependence
, benzodiazepine withdrawal
) · cocaine
, cocaine dependence
) · general
, Physical dependence
, Rebound effect
diagnosed in childhood
|psychology navs: mental processes, disorders, symptoms/signs, speech/voice, psychotherapy